Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,27077673,Cthrough,The ATV mean Cthrough fell from 763.8 ng/mL (CI 95%: 230.3-1297.3) without BOC to 507.7 ng/mL (CI 95%: 164-851.4) with BOC.,"Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27077673/),[ng] / [ml],763.8,3071,DB00034,"Interferon Alfa-2a, Recombinant"
,27077673,Cthrough,The ATV mean Cthrough fell from 763.8 ng/mL (CI 95%: 230.3-1297.3) without BOC to 507.7 ng/mL (CI 95%: 164-851.4) with BOC.,"Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27077673/),[ng] / [ml],507.7,3072,DB00034,"Interferon Alfa-2a, Recombinant"
,16607939,elimination phase half-life,The elimination phase half-life of the fusion protein was 101h after intravenous injection and 68.2h after subcutaneous injection.,[Expression in Pichia pastoris and properties of human serum albumin-interferon alpha2b chimera]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16607939/),h,101,5258,DB00034,"Interferon Alfa-2a, Recombinant"
,16607939,elimination phase half-life,The elimination phase half-life of the fusion protein was 101h after intravenous injection and 68.2h after subcutaneous injection.,[Expression in Pichia pastoris and properties of human serum albumin-interferon alpha2b chimera]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16607939/),h,68.2,5259,DB00034,"Interferon Alfa-2a, Recombinant"
,16607939,Subcutaneous bioavailability,Its Subcutaneous bioavailability was 67.9%.,[Expression in Pichia pastoris and properties of human serum albumin-interferon alpha2b chimera]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16607939/),%,67.9,5260,DB00034,"Interferon Alfa-2a, Recombinant"
,21220001,half-life,"Recombinant human interferon-α-2b (rhIFN), a highly pleiotropic cytokine with a short intrinsic pharmacokinetic half-life when injected subcutaneously (∼2-6 h), was used as a model drug.",Protamine modified metal ion-protein chelate microparticles for sustained release of interferon. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21220001/),h,∼2-6,6812,DB00034,"Interferon Alfa-2a, Recombinant"
,21220001,t(1/2),"First, percentage of chelated rhIFN was lowered (from >99% to ∼90%); second, particle size was gradually increased (from ∼0.45 μm to ∼2 μm); last but important, it extended the release period of the chelate both in vitro (complete release was retarded from 8 h to 48 h) and in vivo (t(1/2) was prolonged from 4.5 h to 15.5 h and mean residence time from 9.4 h to 29.6 h).",Protamine modified metal ion-protein chelate microparticles for sustained release of interferon. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21220001/),h,4.5,6813,DB00034,"Interferon Alfa-2a, Recombinant"
,21220001,t(1/2),"First, percentage of chelated rhIFN was lowered (from >99% to ∼90%); second, particle size was gradually increased (from ∼0.45 μm to ∼2 μm); last but important, it extended the release period of the chelate both in vitro (complete release was retarded from 8 h to 48 h) and in vivo (t(1/2) was prolonged from 4.5 h to 15.5 h and mean residence time from 9.4 h to 29.6 h).",Protamine modified metal ion-protein chelate microparticles for sustained release of interferon. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21220001/),h,15.5,6814,DB00034,"Interferon Alfa-2a, Recombinant"
,21220001,mean residence time,"First, percentage of chelated rhIFN was lowered (from >99% to ∼90%); second, particle size was gradually increased (from ∼0.45 μm to ∼2 μm); last but important, it extended the release period of the chelate both in vitro (complete release was retarded from 8 h to 48 h) and in vivo (t(1/2) was prolonged from 4.5 h to 15.5 h and mean residence time from 9.4 h to 29.6 h).",Protamine modified metal ion-protein chelate microparticles for sustained release of interferon. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21220001/),h,9.4,6815,DB00034,"Interferon Alfa-2a, Recombinant"
,21220001,mean residence time,"First, percentage of chelated rhIFN was lowered (from >99% to ∼90%); second, particle size was gradually increased (from ∼0.45 μm to ∼2 μm); last but important, it extended the release period of the chelate both in vitro (complete release was retarded from 8 h to 48 h) and in vivo (t(1/2) was prolonged from 4.5 h to 15.5 h and mean residence time from 9.4 h to 29.6 h).",Protamine modified metal ion-protein chelate microparticles for sustained release of interferon. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21220001/),h,29.6,6816,DB00034,"Interferon Alfa-2a, Recombinant"
,16078148,bioactivity,"Compared to the polyPEGylated IFN-alpha2b species, the pure (96%) monoPEGylated conjugate retained a significantly higher bioactivity (IU/mg): 1.7x10(4)+/-8.5x10(3) vs. 2.8x10(6)+/-1.4x10(6) for antiviral and 1.9x10(4)+/-9.5x10(3) vs. 3.1x10(6)+/-1.6x10(6) for antiproliferative activity.",PEGylated interferon-alpha2b: a branched 40K polyethylene glycol derivative. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16078148/),[iu] / [mg],1.7x10,6912,DB00034,"Interferon Alfa-2a, Recombinant"
,16078148,bioactivity,"Compared to the polyPEGylated IFN-alpha2b species, the pure (96%) monoPEGylated conjugate retained a significantly higher bioactivity (IU/mg): 1.7x10(4)+/-8.5x10(3) vs. 2.8x10(6)+/-1.4x10(6) for antiviral and 1.9x10(4)+/-9.5x10(3) vs. 3.1x10(6)+/-1.6x10(6) for antiproliferative activity.",PEGylated interferon-alpha2b: a branched 40K polyethylene glycol derivative. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16078148/),[iu] / [mg],2.8x10(6,6913,DB00034,"Interferon Alfa-2a, Recombinant"
,16078148,bioactivity,"Compared to the polyPEGylated IFN-alpha2b species, the pure (96%) monoPEGylated conjugate retained a significantly higher bioactivity (IU/mg): 1.7x10(4)+/-8.5x10(3) vs. 2.8x10(6)+/-1.4x10(6) for antiviral and 1.9x10(4)+/-9.5x10(3) vs. 3.1x10(6)+/-1.6x10(6) for antiproliferative activity.",PEGylated interferon-alpha2b: a branched 40K polyethylene glycol derivative. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16078148/),[iu] / [mg],1.9x10,6914,DB00034,"Interferon Alfa-2a, Recombinant"
,16078148,bioactivity,"Compared to the polyPEGylated IFN-alpha2b species, the pure (96%) monoPEGylated conjugate retained a significantly higher bioactivity (IU/mg): 1.7x10(4)+/-8.5x10(3) vs. 2.8x10(6)+/-1.4x10(6) for antiviral and 1.9x10(4)+/-9.5x10(3) vs. 3.1x10(6)+/-1.6x10(6) for antiproliferative activity.",PEGylated interferon-alpha2b: a branched 40K polyethylene glycol derivative. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16078148/),[iu] / [mg],3.1x10,6915,DB00034,"Interferon Alfa-2a, Recombinant"
,20308381,overall inhibition constant (K*(i)),It has an overall inhibition constant (K*(i)) of 7 nM and a dissociation half-life of 1 to 2 h.,"Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20308381/),nM,7,7020,DB00034,"Interferon Alfa-2a, Recombinant"
,20308381,dissociation half-life,It has an overall inhibition constant (K*(i)) of 7 nM and a dissociation half-life of 1 to 2 h.,"Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20308381/),h,1 to 2,7021,DB00034,"Interferon Alfa-2a, Recombinant"
,20308381,90% effective concentration (EC(90)),SCH 900518 inhibited replicon RNA at a 90% effective concentration (EC(90)) of 40 nM.,"Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20308381/),nM,40,7022,DB00034,"Interferon Alfa-2a, Recombinant"
,12481400,Terminal elimination half lives,"Terminal elimination half lives range from 4-16 hrs, 1-2 hrs and 25-35 min for alpha, beta, gamma respectively.","[The interferons: pharmacology, mechanism of action, tolerance and side effects]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12481400/),h,4-16,7973,DB00034,"Interferon Alfa-2a, Recombinant"
,12481400,Terminal elimination half lives,"Terminal elimination half lives range from 4-16 hrs, 1-2 hrs and 25-35 min for alpha, beta, gamma respectively.","[The interferons: pharmacology, mechanism of action, tolerance and side effects]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12481400/),h,1-2,7974,DB00034,"Interferon Alfa-2a, Recombinant"
,12481400,Terminal elimination half lives,"Terminal elimination half lives range from 4-16 hrs, 1-2 hrs and 25-35 min for alpha, beta, gamma respectively.","[The interferons: pharmacology, mechanism of action, tolerance and side effects]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12481400/),min,25-35,7975,DB00034,"Interferon Alfa-2a, Recombinant"
,17331344,C(max),"Non-pegylated and pegylated IFN-alpha both increased DTX oral bioavailability parameters: C(max) (17.0+/-4.0 microg L(-1) (P < 0.02) and 18+/-5.5 microg L(-1) (P < 0.05), respectively, vs 7.4+/-2.5 microg L(-1) for the control) and AUC (0.036+/-0.010 microg h mL(-1) (P < 0.01) and 0.033+/-0.009 microg h mL(-1) (P < 0.01), respectively, versus 0.012+/-0.004 microg h mL(-1) for the control).","Bioavailability and tissular distribution of docetaxel, a P-glycoprotein substrate, are modified by interferon-alpha in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17331344/),[μg] / [l],17.0,12040,DB00034,"Interferon Alfa-2a, Recombinant"
,17331344,C(max),"Non-pegylated and pegylated IFN-alpha both increased DTX oral bioavailability parameters: C(max) (17.0+/-4.0 microg L(-1) (P < 0.02) and 18+/-5.5 microg L(-1) (P < 0.05), respectively, vs 7.4+/-2.5 microg L(-1) for the control) and AUC (0.036+/-0.010 microg h mL(-1) (P < 0.01) and 0.033+/-0.009 microg h mL(-1) (P < 0.01), respectively, versus 0.012+/-0.004 microg h mL(-1) for the control).","Bioavailability and tissular distribution of docetaxel, a P-glycoprotein substrate, are modified by interferon-alpha in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17331344/),[μg] / [l],18,12041,DB00034,"Interferon Alfa-2a, Recombinant"
,17331344,C(max),"Non-pegylated and pegylated IFN-alpha both increased DTX oral bioavailability parameters: C(max) (17.0+/-4.0 microg L(-1) (P < 0.02) and 18+/-5.5 microg L(-1) (P < 0.05), respectively, vs 7.4+/-2.5 microg L(-1) for the control) and AUC (0.036+/-0.010 microg h mL(-1) (P < 0.01) and 0.033+/-0.009 microg h mL(-1) (P < 0.01), respectively, versus 0.012+/-0.004 microg h mL(-1) for the control).","Bioavailability and tissular distribution of docetaxel, a P-glycoprotein substrate, are modified by interferon-alpha in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17331344/),[μg] / [l],7.4,12042,DB00034,"Interferon Alfa-2a, Recombinant"
,17331344,AUC,"Non-pegylated and pegylated IFN-alpha both increased DTX oral bioavailability parameters: C(max) (17.0+/-4.0 microg L(-1) (P < 0.02) and 18+/-5.5 microg L(-1) (P < 0.05), respectively, vs 7.4+/-2.5 microg L(-1) for the control) and AUC (0.036+/-0.010 microg h mL(-1) (P < 0.01) and 0.033+/-0.009 microg h mL(-1) (P < 0.01), respectively, versus 0.012+/-0.004 microg h mL(-1) for the control).","Bioavailability and tissular distribution of docetaxel, a P-glycoprotein substrate, are modified by interferon-alpha in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17331344/),[h·μg] / [ml],0.036,12043,DB00034,"Interferon Alfa-2a, Recombinant"
,17331344,AUC,"Non-pegylated and pegylated IFN-alpha both increased DTX oral bioavailability parameters: C(max) (17.0+/-4.0 microg L(-1) (P < 0.02) and 18+/-5.5 microg L(-1) (P < 0.05), respectively, vs 7.4+/-2.5 microg L(-1) for the control) and AUC (0.036+/-0.010 microg h mL(-1) (P < 0.01) and 0.033+/-0.009 microg h mL(-1) (P < 0.01), respectively, versus 0.012+/-0.004 microg h mL(-1) for the control).","Bioavailability and tissular distribution of docetaxel, a P-glycoprotein substrate, are modified by interferon-alpha in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17331344/),[h·μg] / [ml],0.033,12044,DB00034,"Interferon Alfa-2a, Recombinant"
,17331344,AUC,"Non-pegylated and pegylated IFN-alpha both increased DTX oral bioavailability parameters: C(max) (17.0+/-4.0 microg L(-1) (P < 0.02) and 18+/-5.5 microg L(-1) (P < 0.05), respectively, vs 7.4+/-2.5 microg L(-1) for the control) and AUC (0.036+/-0.010 microg h mL(-1) (P < 0.01) and 0.033+/-0.009 microg h mL(-1) (P < 0.01), respectively, versus 0.012+/-0.004 microg h mL(-1) for the control).","Bioavailability and tissular distribution of docetaxel, a P-glycoprotein substrate, are modified by interferon-alpha in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17331344/),[h·μg] / [ml],0.012,12045,DB00034,"Interferon Alfa-2a, Recombinant"
,24093213,MTD,The MTD of cyclical oral TMZ was 100 mg/m² on days 1-7 and 15-21 when combined with weekly subcutaneous PEG-IFNα-2b at 1.5 mcg/kg/week on 28 days cycles.,"A phase I, dose-escalation study of cyclical weekly oral temozolomide and weekly PEG-interferon alpha-2b in patients with refractory or advanced solid tumours. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24093213/),[mg] / [m²],100,15027,DB00034,"Interferon Alfa-2a, Recombinant"
,9413958,blood concentrations,"Maximum 13cisRA blood concentrations usually occurred 4 h after drug administration, with average values of 406 and 633 ng ml(-1) (i.e. 1.3 and 2.1 microM) after the 20 and 40 mg dose respectively.",Pharmacokinetics and effects on plasma retinol concentrations of 13-cis-retinoic acid in melanoma patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9413958/),[ng] / [ml],406,19154,DB00034,"Interferon Alfa-2a, Recombinant"
,9413958,blood concentrations,"Maximum 13cisRA blood concentrations usually occurred 4 h after drug administration, with average values of 406 and 633 ng ml(-1) (i.e. 1.3 and 2.1 microM) after the 20 and 40 mg dose respectively.",Pharmacokinetics and effects on plasma retinol concentrations of 13-cis-retinoic acid in melanoma patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9413958/),[ng] / [ml],633,19155,DB00034,"Interferon Alfa-2a, Recombinant"
,9413958,blood concentrations,"Maximum 13cisRA blood concentrations usually occurred 4 h after drug administration, with average values of 406 and 633 ng ml(-1) (i.e. 1.3 and 2.1 microM) after the 20 and 40 mg dose respectively.",Pharmacokinetics and effects on plasma retinol concentrations of 13-cis-retinoic acid in melanoma patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9413958/),μM,1.3,19156,DB00034,"Interferon Alfa-2a, Recombinant"
,9413958,blood concentrations,"Maximum 13cisRA blood concentrations usually occurred 4 h after drug administration, with average values of 406 and 633 ng ml(-1) (i.e. 1.3 and 2.1 microM) after the 20 and 40 mg dose respectively.",Pharmacokinetics and effects on plasma retinol concentrations of 13-cis-retinoic acid in melanoma patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9413958/),μM,2.1,19157,DB00034,"Interferon Alfa-2a, Recombinant"
,9413958,half-life (t(1/2)),The average half-life (t(1/2)) was approximately 30 h.,Pharmacokinetics and effects on plasma retinol concentrations of 13-cis-retinoic acid in melanoma patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9413958/),h,30,19158,DB00034,"Interferon Alfa-2a, Recombinant"
,16939523,clearance,The clearance at treatment week 4 was 42.3 l day(-1) (patients with CLcr 120 ml min(-1)) with interpatient variability 30%.,Dose selection and population pharmacokinetics of PEG-Intron in patients with chronic myelogenous leukaemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16939523/),[l] / [day],42.3,29030,DB00034,"Interferon Alfa-2a, Recombinant"
,15767790,time to progression (TTP),"Median time to progression (TTP) and overall survival were 7.1 months and 13.0 months, respectively.",Short communication: the efficacy of fixed dose rate infusion of gemcitabine combined with IFN-alpha2a in patients with advanced refractory renal cell carcinoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15767790/),month,7.1,37685,DB00034,"Interferon Alfa-2a, Recombinant"
,15767790,overall survival,"Median time to progression (TTP) and overall survival were 7.1 months and 13.0 months, respectively.",Short communication: the efficacy of fixed dose rate infusion of gemcitabine combined with IFN-alpha2a in patients with advanced refractory renal cell carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15767790/),month,13.0,37686,DB00034,"Interferon Alfa-2a, Recombinant"
,25297637,plasma half-life,"After s.c. injection of PEG-IFN-SA at 1.5 μg kg(-1) , the mean geometric mean values of plasma half-life, time to maximal concentration, maximal concentration and AUC(0-168h) were 55.3 h, 26.9 h, 0.53 μg l(-1) and 44.0 μg l(-1) h, respectively.",A pharmacokinetic and pharmacodynamic comparison of a novel pegylated recombinant consensus interferon-α variant with peginterferon-α-2a in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25297637/),h,55.3,38669,DB00034,"Interferon Alfa-2a, Recombinant"
,25297637,time to maximal concentration,"After s.c. injection of PEG-IFN-SA at 1.5 μg kg(-1) , the mean geometric mean values of plasma half-life, time to maximal concentration, maximal concentration and AUC(0-168h) were 55.3 h, 26.9 h, 0.53 μg l(-1) and 44.0 μg l(-1) h, respectively.",A pharmacokinetic and pharmacodynamic comparison of a novel pegylated recombinant consensus interferon-α variant with peginterferon-α-2a in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25297637/),h,26.9,38670,DB00034,"Interferon Alfa-2a, Recombinant"
,25297637,time to maximal concentration,"After s.c. injection of PEG-IFN-SA at 1.5 μg kg(-1) , the mean geometric mean values of plasma half-life, time to maximal concentration, maximal concentration and AUC(0-168h) were 55.3 h, 26.9 h, 0.53 μg l(-1) and 44.0 μg l(-1) h, respectively.",A pharmacokinetic and pharmacodynamic comparison of a novel pegylated recombinant consensus interferon-α variant with peginterferon-α-2a in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25297637/),[μg] / [l],0.53,38671,DB00034,"Interferon Alfa-2a, Recombinant"
,25297637,maximal concentration,"After s.c. injection of PEG-IFN-SA at 1.5 μg kg(-1) , the mean geometric mean values of plasma half-life, time to maximal concentration, maximal concentration and AUC(0-168h) were 55.3 h, 26.9 h, 0.53 μg l(-1) and 44.0 μg l(-1) h, respectively.",A pharmacokinetic and pharmacodynamic comparison of a novel pegylated recombinant consensus interferon-α variant with peginterferon-α-2a in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25297637/),h,26.9,38672,DB00034,"Interferon Alfa-2a, Recombinant"
,25297637,maximal concentration,"After s.c. injection of PEG-IFN-SA at 1.5 μg kg(-1) , the mean geometric mean values of plasma half-life, time to maximal concentration, maximal concentration and AUC(0-168h) were 55.3 h, 26.9 h, 0.53 μg l(-1) and 44.0 μg l(-1) h, respectively.",A pharmacokinetic and pharmacodynamic comparison of a novel pegylated recombinant consensus interferon-α variant with peginterferon-α-2a in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25297637/),[μg] / [l],0.53,38673,DB00034,"Interferon Alfa-2a, Recombinant"
,25297637,AUC(0-168h),"After s.c. injection of PEG-IFN-SA at 1.5 μg kg(-1) , the mean geometric mean values of plasma half-life, time to maximal concentration, maximal concentration and AUC(0-168h) were 55.3 h, 26.9 h, 0.53 μg l(-1) and 44.0 μg l(-1) h, respectively.",A pharmacokinetic and pharmacodynamic comparison of a novel pegylated recombinant consensus interferon-α variant with peginterferon-α-2a in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25297637/),[h·μg] / [l],44.0,38674,DB00034,"Interferon Alfa-2a, Recombinant"
,7710452,gamma-HL,"A statistical significant influence in regard to the terminal elimination half-life (gamma-HL) and the total clearance (CLtot) was found, indicating a reduction of gamma-HL from 18.18 +/- 16.7 for EPR to 8.47 +/- 8.67 h for EPR+IFN and a reduction of the total clearance from 72.33 +/- 55.4 ml/min for EPR to 48.41 +/- 12.7 ml/min for EPR+IFN.",Pharmacokinetic drug interaction between epirubicin and interferon-alpha-2b in serum and red blood cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7710452/),h,18.18,39426,DB00034,"Interferon Alfa-2a, Recombinant"
,7710452,gamma-HL,"A statistical significant influence in regard to the terminal elimination half-life (gamma-HL) and the total clearance (CLtot) was found, indicating a reduction of gamma-HL from 18.18 +/- 16.7 for EPR to 8.47 +/- 8.67 h for EPR+IFN and a reduction of the total clearance from 72.33 +/- 55.4 ml/min for EPR to 48.41 +/- 12.7 ml/min for EPR+IFN.",Pharmacokinetic drug interaction between epirubicin and interferon-alpha-2b in serum and red blood cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7710452/),h,8.47,39427,DB00034,"Interferon Alfa-2a, Recombinant"
,7710452,total clearance,"A statistical significant influence in regard to the terminal elimination half-life (gamma-HL) and the total clearance (CLtot) was found, indicating a reduction of gamma-HL from 18.18 +/- 16.7 for EPR to 8.47 +/- 8.67 h for EPR+IFN and a reduction of the total clearance from 72.33 +/- 55.4 ml/min for EPR to 48.41 +/- 12.7 ml/min for EPR+IFN.",Pharmacokinetic drug interaction between epirubicin and interferon-alpha-2b in serum and red blood cells. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7710452/),[ml] / [min],72.33,39428,DB00034,"Interferon Alfa-2a, Recombinant"
,7710452,total clearance,"A statistical significant influence in regard to the terminal elimination half-life (gamma-HL) and the total clearance (CLtot) was found, indicating a reduction of gamma-HL from 18.18 +/- 16.7 for EPR to 8.47 +/- 8.67 h for EPR+IFN and a reduction of the total clearance from 72.33 +/- 55.4 ml/min for EPR to 48.41 +/- 12.7 ml/min for EPR+IFN.",Pharmacokinetic drug interaction between epirubicin and interferon-alpha-2b in serum and red blood cells. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7710452/),[ml] / [min],48.41,39429,DB00034,"Interferon Alfa-2a, Recombinant"
,7710452,area under the concentration-time curve (AUC,"The area under the concentration-time curve (AUC, according to the 3-compartment model) increases under the influence of IFN from 2004 +/- 1105 ng/ml.h for EPR up to 2582 +/- 1024 ng/ml.h for EPR+IFN.",Pharmacokinetic drug interaction between epirubicin and interferon-alpha-2b in serum and red blood cells. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7710452/),[ng] / [h·ml],2004,39430,DB00034,"Interferon Alfa-2a, Recombinant"
,7710452,area under the concentration-time curve (AUC,"The area under the concentration-time curve (AUC, according to the 3-compartment model) increases under the influence of IFN from 2004 +/- 1105 ng/ml.h for EPR up to 2582 +/- 1024 ng/ml.h for EPR+IFN.",Pharmacokinetic drug interaction between epirubicin and interferon-alpha-2b in serum and red blood cells. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7710452/),[ng] / [h·ml],2582,39431,DB00034,"Interferon Alfa-2a, Recombinant"
,24092661,Ctrough levels,"The mean telaprevir Ctrough levels at days 3, 7 and 14 of SVR patients (2.748, 2.733 and 2.999 μg/mL, respectively) were significantly higher than those of non-SVR patients (1.616, 1.788 and 2.314 μg/mL, respectively) (all P < 0.05).",Therapeutic drug monitoring of telaprevir in chronic hepatitis C patients receiving telaprevir-based triple therapy is useful for predicting virological response. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24092661/),[μg] / [ml],2.748,40515,DB00034,"Interferon Alfa-2a, Recombinant"
,24092661,Ctrough levels,"The mean telaprevir Ctrough levels at days 3, 7 and 14 of SVR patients (2.748, 2.733 and 2.999 μg/mL, respectively) were significantly higher than those of non-SVR patients (1.616, 1.788 and 2.314 μg/mL, respectively) (all P < 0.05).",Therapeutic drug monitoring of telaprevir in chronic hepatitis C patients receiving telaprevir-based triple therapy is useful for predicting virological response. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24092661/),[μg] / [ml],2.733,40516,DB00034,"Interferon Alfa-2a, Recombinant"
,24092661,Ctrough levels,"The mean telaprevir Ctrough levels at days 3, 7 and 14 of SVR patients (2.748, 2.733 and 2.999 μg/mL, respectively) were significantly higher than those of non-SVR patients (1.616, 1.788 and 2.314 μg/mL, respectively) (all P < 0.05).",Therapeutic drug monitoring of telaprevir in chronic hepatitis C patients receiving telaprevir-based triple therapy is useful for predicting virological response. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24092661/),[μg] / [ml],2.999,40517,DB00034,"Interferon Alfa-2a, Recombinant"
,24092661,Ctrough levels,"The mean telaprevir Ctrough levels at days 3, 7 and 14 of SVR patients (2.748, 2.733 and 2.999 μg/mL, respectively) were significantly higher than those of non-SVR patients (1.616, 1.788 and 2.314 μg/mL, respectively) (all P < 0.05).",Therapeutic drug monitoring of telaprevir in chronic hepatitis C patients receiving telaprevir-based triple therapy is useful for predicting virological response. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24092661/),[μg] / [ml],1.616,40518,DB00034,"Interferon Alfa-2a, Recombinant"
,24092661,Ctrough levels,"The mean telaprevir Ctrough levels at days 3, 7 and 14 of SVR patients (2.748, 2.733 and 2.999 μg/mL, respectively) were significantly higher than those of non-SVR patients (1.616, 1.788 and 2.314 μg/mL, respectively) (all P < 0.05).",Therapeutic drug monitoring of telaprevir in chronic hepatitis C patients receiving telaprevir-based triple therapy is useful for predicting virological response. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24092661/),[μg] / [ml],1.788,40519,DB00034,"Interferon Alfa-2a, Recombinant"
,24092661,Ctrough levels,"The mean telaprevir Ctrough levels at days 3, 7 and 14 of SVR patients (2.748, 2.733 and 2.999 μg/mL, respectively) were significantly higher than those of non-SVR patients (1.616, 1.788 and 2.314 μg/mL, respectively) (all P < 0.05).",Therapeutic drug monitoring of telaprevir in chronic hepatitis C patients receiving telaprevir-based triple therapy is useful for predicting virological response. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24092661/),[μg] / [ml],2.314,40520,DB00034,"Interferon Alfa-2a, Recombinant"
,20561702,cell loss rate (delta),"The maximum PEG-IFN effectiveness during the first PEG-IFN dose and the HCV-infected cell loss rate (delta), were significantly higher in SVRs compared to non-SVRs (median 95% vs. 86% [p=0.013], 0.27 vs. 0.11 day(-1) [p=0.006], respectively).",Pharmacodynamics of PEG-IFN-alpha-2a in HIV/HCV co-infected patients: implications for treatment outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20561702/),1/[day],0.27,41009,DB00034,"Interferon Alfa-2a, Recombinant"
,20561702,cell loss rate (delta),"The maximum PEG-IFN effectiveness during the first PEG-IFN dose and the HCV-infected cell loss rate (delta), were significantly higher in SVRs compared to non-SVRs (median 95% vs. 86% [p=0.013], 0.27 vs. 0.11 day(-1) [p=0.006], respectively).",Pharmacodynamics of PEG-IFN-alpha-2a in HIV/HCV co-infected patients: implications for treatment outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20561702/),1/[day],0.11,41010,DB00034,"Interferon Alfa-2a, Recombinant"
,20561702,delta,Genotype 1 had a significantly lower delta compared to genotype 3 (median 0.14 vs. 0.23 day(-1) [p=0.021]).,Pharmacodynamics of PEG-IFN-alpha-2a in HIV/HCV co-infected patients: implications for treatment outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20561702/),1/[day],0.14,41011,DB00034,"Interferon Alfa-2a, Recombinant"
,20561702,delta,Genotype 1 had a significantly lower delta compared to genotype 3 (median 0.14 vs. 0.23 day(-1) [p=0.021]).,Pharmacodynamics of PEG-IFN-alpha-2a in HIV/HCV co-infected patients: implications for treatment outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20561702/),1/[day],0.23,41012,DB00034,"Interferon Alfa-2a, Recombinant"
,20561702,EC(50),The PEG-IFN concentration that decreased HCV production by 50% (EC(50)) was lower in genotype 3 compared to genotype 1 (median 1.3 vs. 3.4 [p=0.034]).,Pharmacodynamics of PEG-IFN-alpha-2a in HIV/HCV co-infected patients: implications for treatment outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20561702/),,1.3,41013,DB00034,"Interferon Alfa-2a, Recombinant"
,20561702,EC(50),The PEG-IFN concentration that decreased HCV production by 50% (EC(50)) was lower in genotype 3 compared to genotype 1 (median 1.3 vs. 3.4 [p=0.034]).,Pharmacodynamics of PEG-IFN-alpha-2a in HIV/HCV co-infected patients: implications for treatment outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20561702/),,3.4,41014,DB00034,"Interferon Alfa-2a, Recombinant"
,24005956,rapid virologic response rates,"High rapid virologic response rates (83, 90, and 8 % for simeprevir 50 mg combined, 100 mg combined, and PR48 groups, respectively) led to high sustained virologic response rates (77-92 %, compared with 46 % for PR48).",Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24005956/),%,83,42354,DB00034,"Interferon Alfa-2a, Recombinant"
,24005956,rapid virologic response rates,"High rapid virologic response rates (83, 90, and 8 % for simeprevir 50 mg combined, 100 mg combined, and PR48 groups, respectively) led to high sustained virologic response rates (77-92 %, compared with 46 % for PR48).",Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24005956/),%,90,42355,DB00034,"Interferon Alfa-2a, Recombinant"
,24005956,rapid virologic response rates,"High rapid virologic response rates (83, 90, and 8 % for simeprevir 50 mg combined, 100 mg combined, and PR48 groups, respectively) led to high sustained virologic response rates (77-92 %, compared with 46 % for PR48).",Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24005956/),%,8,42356,DB00034,"Interferon Alfa-2a, Recombinant"
,24005956,sustained v,"High rapid virologic response rates (83, 90, and 8 % for simeprevir 50 mg combined, 100 mg combined, and PR48 groups, respectively) led to high sustained virologic response rates (77-92 %, compared with 46 % for PR48).",Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24005956/),%,77-92,42357,DB00034,"Interferon Alfa-2a, Recombinant"
,24005956,sustained v,"High rapid virologic response rates (83, 90, and 8 % for simeprevir 50 mg combined, 100 mg combined, and PR48 groups, respectively) led to high sustained virologic response rates (77-92 %, compared with 46 % for PR48).",Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24005956/),%,46,42358,DB00034,"Interferon Alfa-2a, Recombinant"
,24005956,Relapse rates,"Relapse rates in simeprevir-treated patients were low (8-17 %, compared with 36 % for the PR48 group).",Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24005956/),,8,42359,DB00034,"Interferon Alfa-2a, Recombinant"
,24005956,Relapse rates,"Relapse rates in simeprevir-treated patients were low (8-17 %, compared with 36 % for the PR48 group).",Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24005956/),,36,42360,DB00034,"Interferon Alfa-2a, Recombinant"
,29301580,Tmax,Analysis of time parameters revealed that BIP48 remained in the body significantly longer than PEGASYS® (Tmax: 73 vs. 54 h [p = 0.0010]; MRT: 133 vs. 115 h [p = 0.0324]; ke: 0.011 vs. 0.013 h(-1) [p = 0.0153]; t1/2: 192 vs. 108 h [p = 0.0218]).,Pharmacokinetics comparison of two pegylated interferon alfa formulations in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29301580/),h,73,43973,DB00034,"Interferon Alfa-2a, Recombinant"
,29301580,Tmax,Analysis of time parameters revealed that BIP48 remained in the body significantly longer than PEGASYS® (Tmax: 73 vs. 54 h [p = 0.0010]; MRT: 133 vs. 115 h [p = 0.0324]; ke: 0.011 vs. 0.013 h(-1) [p = 0.0153]; t1/2: 192 vs. 108 h [p = 0.0218]).,Pharmacokinetics comparison of two pegylated interferon alfa formulations in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29301580/),h,54,43974,DB00034,"Interferon Alfa-2a, Recombinant"
,29301580,MRT,Analysis of time parameters revealed that BIP48 remained in the body significantly longer than PEGASYS® (Tmax: 73 vs. 54 h [p = 0.0010]; MRT: 133 vs. 115 h [p = 0.0324]; ke: 0.011 vs. 0.013 h(-1) [p = 0.0153]; t1/2: 192 vs. 108 h [p = 0.0218]).,Pharmacokinetics comparison of two pegylated interferon alfa formulations in healthy volunteers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29301580/),h,133,43975,DB00034,"Interferon Alfa-2a, Recombinant"
,29301580,MRT,Analysis of time parameters revealed that BIP48 remained in the body significantly longer than PEGASYS® (Tmax: 73 vs. 54 h [p = 0.0010]; MRT: 133 vs. 115 h [p = 0.0324]; ke: 0.011 vs. 0.013 h(-1) [p = 0.0153]; t1/2: 192 vs. 108 h [p = 0.0218]).,Pharmacokinetics comparison of two pegylated interferon alfa formulations in healthy volunteers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29301580/),h,115,43976,DB00034,"Interferon Alfa-2a, Recombinant"
,29301580,ke,Analysis of time parameters revealed that BIP48 remained in the body significantly longer than PEGASYS® (Tmax: 73 vs. 54 h [p = 0.0010]; MRT: 133 vs. 115 h [p = 0.0324]; ke: 0.011 vs. 0.013 h(-1) [p = 0.0153]; t1/2: 192 vs. 108 h [p = 0.0218]).,Pharmacokinetics comparison of two pegylated interferon alfa formulations in healthy volunteers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29301580/),1/[h],0.011,43977,DB00034,"Interferon Alfa-2a, Recombinant"
,29301580,ke,Analysis of time parameters revealed that BIP48 remained in the body significantly longer than PEGASYS® (Tmax: 73 vs. 54 h [p = 0.0010]; MRT: 133 vs. 115 h [p = 0.0324]; ke: 0.011 vs. 0.013 h(-1) [p = 0.0153]; t1/2: 192 vs. 108 h [p = 0.0218]).,Pharmacokinetics comparison of two pegylated interferon alfa formulations in healthy volunteers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29301580/),1/[h],0.013,43978,DB00034,"Interferon Alfa-2a, Recombinant"
,29301580,t1/2,Analysis of time parameters revealed that BIP48 remained in the body significantly longer than PEGASYS® (Tmax: 73 vs. 54 h [p = 0.0010]; MRT: 133 vs. 115 h [p = 0.0324]; ke: 0.011 vs. 0.013 h(-1) [p = 0.0153]; t1/2: 192 vs. 108 h [p = 0.0218]).,Pharmacokinetics comparison of two pegylated interferon alfa formulations in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29301580/),h,192,43979,DB00034,"Interferon Alfa-2a, Recombinant"
,29301580,t1/2,Analysis of time parameters revealed that BIP48 remained in the body significantly longer than PEGASYS® (Tmax: 73 vs. 54 h [p = 0.0010]; MRT: 133 vs. 115 h [p = 0.0324]; ke: 0.011 vs. 0.013 h(-1) [p = 0.0153]; t1/2: 192 vs. 108 h [p = 0.0218]).,Pharmacokinetics comparison of two pegylated interferon alfa formulations in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29301580/),h,108,43980,DB00034,"Interferon Alfa-2a, Recombinant"
,1781811,bioavailability,The bioavailability of 5FU (compared as the AUC0-60 values) is elevated to 80%.,[Pharmacokinetic aspects of the combination of interferon-alpha-2b and folic acid with fluorouracil]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1781811/),%,80,48077,DB00034,"Interferon Alfa-2a, Recombinant"
,1781811,bioavailability,"In contrary, the combination of IFN with FA leads to a non-significant change of the 5FU pharmacokinetics, although the bioavailability is increased to 18%.",[Pharmacokinetic aspects of the combination of interferon-alpha-2b and folic acid with fluorouracil]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1781811/),%,18,48078,DB00034,"Interferon Alfa-2a, Recombinant"
,17118126,clearance,"Lean body weight (range 41-91 kg) was the only covariate with a clinically significant influence on ribavirin pharmacokinetics, affecting clearance (15.3-23.9 l h(-1)) and the volume of the larger peripheral compartment.",Pharmacokinetics of ribavirin in patients with hepatitis C virus. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17118126/),[l] / [h],15.3-23.9,51751,DB00034,"Interferon Alfa-2a, Recombinant"
,16144928,DLT,"With the addition of ara-C, the DLT was reached at 540 microg/wk.",Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16144928/),[μg] / [wk],540,55567,DB00034,"Interferon Alfa-2a, Recombinant"
,16144928,serum peak concentration (C(max)),"The mean serum peak concentration (C(max)) of PEG-IFN increased from 9.4 to 28 ng/mL as the dose increased from 270 to 450 microg/wk, with no further increases in C(max) at higher dose levels.",Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16144928/),[ng] / [ml],9.4,55568,DB00034,"Interferon Alfa-2a, Recombinant"
,16144928,serum peak concentration (C(max)),"The mean serum peak concentration (C(max)) of PEG-IFN increased from 9.4 to 28 ng/mL as the dose increased from 270 to 450 microg/wk, with no further increases in C(max) at higher dose levels.",Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16144928/),[ng] / [ml],28,55569,DB00034,"Interferon Alfa-2a, Recombinant"
,16144928,area under the serum concentration-time curve (AUC),"The mean +/- SD area under the serum concentration-time curve (AUC) calculated after the first dose also increased from 1,022 +/- 694 to 3,343 +/- 2,728 ng hour/mL as dose was increased from 270 to 450 microg/wk, showing a dose-related increase in systemic exposure of PEG-IFN.",Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16144928/),[h·ng] / [ml],"1,022",55570,DB00034,"Interferon Alfa-2a, Recombinant"
,16144928,area under the serum concentration-time curve (AUC),"The mean +/- SD area under the serum concentration-time curve (AUC) calculated after the first dose also increased from 1,022 +/- 694 to 3,343 +/- 2,728 ng hour/mL as dose was increased from 270 to 450 microg/wk, showing a dose-related increase in systemic exposure of PEG-IFN.",Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16144928/),[h·ng] / [ml],"3,343",55571,DB00034,"Interferon Alfa-2a, Recombinant"
,16151670,AUCs,"The pharmacokinetics of i.v. administered digoxin was not modified by IFN-alpha, but a dose-dependent increase in areas under the curve (AUCs) was observed in the orally administered digoxin parameters in rats (AUCs: 392 +/- 83 min microg L(-1), p < 0.01 and 550 +/- 97 min microg L(-1), p < 0.001, respectively, vs. 286 +/- 111 min microg L(-1) for control).",Modification of the P-glycoprotein dependent pharmacokinetics of digoxin in rats by human recombinant interferon-alpha. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16151670/),[min·μg] / [l],392,57769,DB00034,"Interferon Alfa-2a, Recombinant"
,16151670,AUCs,"The pharmacokinetics of i.v. administered digoxin was not modified by IFN-alpha, but a dose-dependent increase in areas under the curve (AUCs) was observed in the orally administered digoxin parameters in rats (AUCs: 392 +/- 83 min microg L(-1), p < 0.01 and 550 +/- 97 min microg L(-1), p < 0.001, respectively, vs. 286 +/- 111 min microg L(-1) for control).",Modification of the P-glycoprotein dependent pharmacokinetics of digoxin in rats by human recombinant interferon-alpha. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16151670/),[min·μg] / [l],550,57770,DB00034,"Interferon Alfa-2a, Recombinant"
,16151670,AUCs,"The pharmacokinetics of i.v. administered digoxin was not modified by IFN-alpha, but a dose-dependent increase in areas under the curve (AUCs) was observed in the orally administered digoxin parameters in rats (AUCs: 392 +/- 83 min microg L(-1), p < 0.01 and 550 +/- 97 min microg L(-1), p < 0.001, respectively, vs. 286 +/- 111 min microg L(-1) for control).",Modification of the P-glycoprotein dependent pharmacokinetics of digoxin in rats by human recombinant interferon-alpha. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16151670/),[min·μg] / [l],286,57771,DB00034,"Interferon Alfa-2a, Recombinant"
,2178336,peak concentrations,"Subcutaneous injection of 1.6 x 10(6) U of human recombinant IFN-alpha 2b per kg delivered peak concentrations in plasma of 3,600 U/ml at 2 h postadministration with a half-life of elimination of 2.9 h.",Alpha interferon (2b) in combination with zidovudine for the treatment of presymptomatic feline leukemia virus-induced immunodeficiency syndrome. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2178336/),[u] / [ml],"3,600",59946,DB00034,"Interferon Alfa-2a, Recombinant"
,2178336,half-life of elimination,"Subcutaneous injection of 1.6 x 10(6) U of human recombinant IFN-alpha 2b per kg delivered peak concentrations in plasma of 3,600 U/ml at 2 h postadministration with a half-life of elimination of 2.9 h.",Alpha interferon (2b) in combination with zidovudine for the treatment of presymptomatic feline leukemia virus-induced immunodeficiency syndrome. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2178336/),h,2.9,59947,DB00034,"Interferon Alfa-2a, Recombinant"
,2178336,peak concentrations,Oral administration of AZT (20 mg/kg three times daily) resulted in peak concentrations in plasma of 3 micrograms/ml at 2 h with a half-life of elimination of approximately 1.60 h.,Alpha interferon (2b) in combination with zidovudine for the treatment of presymptomatic feline leukemia virus-induced immunodeficiency syndrome. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2178336/),[μg] / [ml],3,59948,DB00034,"Interferon Alfa-2a, Recombinant"
,2178336,half-life of elimination,Oral administration of AZT (20 mg/kg three times daily) resulted in peak concentrations in plasma of 3 micrograms/ml at 2 h with a half-life of elimination of approximately 1.60 h.,Alpha interferon (2b) in combination with zidovudine for the treatment of presymptomatic feline leukemia virus-induced immunodeficiency syndrome. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2178336/),h,1.60,59949,DB00034,"Interferon Alfa-2a, Recombinant"
,8426214,maximally tolerated dose (MTD),"After decreasing the 5-FU dose to 640 mg/m2/d, the maximally tolerated dose (MTD) of IFN was 2.0 x 10(6) U/m2/d.","Cisplatin, fluorouracil, and leucovorin augmented by interferon alfa-2b in head and neck cancer: a clinical and pharmacologic analysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8426214/),,2,65829,DB00034,"Interferon Alfa-2a, Recombinant"
,9616292,t1/2,"A 200 mg/kg i.p. bolus dose of 5-FU was eliminated from control tumours with a t1/2 of 25.4 +/- 2 min (mean +/- SEM, n = 11), while both thymidine (500 mg/kg) and interferon (50,000 IU/mouse) significantly increased t1/2 to 36.5 +/- 6.1 (n = 5) and 48.1 +/- 13.6 min (n = 4), respectively (P = 0.04, Gabriel's ANOVA).",A pharmacokinetic and pharmacodynamic study in vivo of human HT29 tumours using 19F and 31P magnetic resonance spectroscopy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9616292/),min,25.4,66154,DB00034,"Interferon Alfa-2a, Recombinant"
,9616292,t1/2,"A 200 mg/kg i.p. bolus dose of 5-FU was eliminated from control tumours with a t1/2 of 25.4 +/- 2 min (mean +/- SEM, n = 11), while both thymidine (500 mg/kg) and interferon (50,000 IU/mouse) significantly increased t1/2 to 36.5 +/- 6.1 (n = 5) and 48.1 +/- 13.6 min (n = 4), respectively (P = 0.04, Gabriel's ANOVA).",A pharmacokinetic and pharmacodynamic study in vivo of human HT29 tumours using 19F and 31P magnetic resonance spectroscopy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9616292/),min,36.5,66155,DB00034,"Interferon Alfa-2a, Recombinant"
,9616292,t1/2,"A 200 mg/kg i.p. bolus dose of 5-FU was eliminated from control tumours with a t1/2 of 25.4 +/- 2 min (mean +/- SEM, n = 11), while both thymidine (500 mg/kg) and interferon (50,000 IU/mouse) significantly increased t1/2 to 36.5 +/- 6.1 (n = 5) and 48.1 +/- 13.6 min (n = 4), respectively (P = 0.04, Gabriel's ANOVA).",A pharmacokinetic and pharmacodynamic study in vivo of human HT29 tumours using 19F and 31P magnetic resonance spectroscopy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9616292/),min,48.1,66156,DB00034,"Interferon Alfa-2a, Recombinant"
,9616292,pHint,"31P-MRS of HT29 tumours showed that 2 and 24 h after i.p. injections of interferon there was a significant increase in the pHint of 0.3 +/- 0.04 units (P = 0.002), while pHext and the tumour NTP/Pi ratio were unchanged.",A pharmacokinetic and pharmacodynamic study in vivo of human HT29 tumours using 19F and 31P magnetic resonance spectroscopy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9616292/),units,0.3,66157,DB00034,"Interferon Alfa-2a, Recombinant"
,19523011,C(max),"In the 180 microg week(-1) group mean +/- SD steady-state (week 12) estimates of AUC(0-168) (ng h(-1) ml(-1)), C(max) (ng ml(-1)) and CL/F (l h(-1)) were 2154 +/- 919, 13.8 +/- 6.7 and 0.102 +/- 0.051, respectively.",Pharmacokinetics and response of obese patients with chronic hepatitis C treated with different doses of PEG-IFN alpha-2a (40KD) (PEGASYS). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19523011/),[l] / [h],2154,69448,DB00034,"Interferon Alfa-2a, Recombinant"
,19523011,C(max),"In the 180 microg week(-1) group mean +/- SD steady-state (week 12) estimates of AUC(0-168) (ng h(-1) ml(-1)), C(max) (ng ml(-1)) and CL/F (l h(-1)) were 2154 +/- 919, 13.8 +/- 6.7 and 0.102 +/- 0.051, respectively.",Pharmacokinetics and response of obese patients with chronic hepatitis C treated with different doses of PEG-IFN alpha-2a (40KD) (PEGASYS). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19523011/),,13.8,69449,DB00034,"Interferon Alfa-2a, Recombinant"
,19523011,CL/F,"In the 180 microg week(-1) group mean +/- SD steady-state (week 12) estimates of AUC(0-168) (ng h(-1) ml(-1)), C(max) (ng ml(-1)) and CL/F (l h(-1)) were 2154 +/- 919, 13.8 +/- 6.7 and 0.102 +/- 0.051, respectively.",Pharmacokinetics and response of obese patients with chronic hepatitis C treated with different doses of PEG-IFN alpha-2a (40KD) (PEGASYS). ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19523011/),[l] / [h],2154,69450,DB00034,"Interferon Alfa-2a, Recombinant"
,19523011,CL/F,"In the 180 microg week(-1) group mean +/- SD steady-state (week 12) estimates of AUC(0-168) (ng h(-1) ml(-1)), C(max) (ng ml(-1)) and CL/F (l h(-1)) were 2154 +/- 919, 13.8 +/- 6.7 and 0.102 +/- 0.051, respectively.",Pharmacokinetics and response of obese patients with chronic hepatitis C treated with different doses of PEG-IFN alpha-2a (40KD) (PEGASYS). ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19523011/),,13.8,69451,DB00034,"Interferon Alfa-2a, Recombinant"
,19523011,CL/F,"In the 180 microg week(-1) group mean +/- SD steady-state (week 12) estimates of AUC(0-168) (ng h(-1) ml(-1)), C(max) (ng ml(-1)) and CL/F (l h(-1)) were 2154 +/- 919, 13.8 +/- 6.7 and 0.102 +/- 0.051, respectively.",Pharmacokinetics and response of obese patients with chronic hepatitis C treated with different doses of PEG-IFN alpha-2a (40KD) (PEGASYS). ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19523011/),,0.102,69452,DB00034,"Interferon Alfa-2a, Recombinant"
,19523011,C(trough),The mean (range) C(trough) (ng ml(-1)) was 11.2 (4.4-18.5) in the 180 microg week(-1) group and 16.1 (0.4-44.2) in the 270 microg week(-1) group.,Pharmacokinetics and response of obese patients with chronic hepatitis C treated with different doses of PEG-IFN alpha-2a (40KD) (PEGASYS). ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19523011/),[ng] / [ml],11.2,69453,DB00034,"Interferon Alfa-2a, Recombinant"
,19523011,C(trough),The mean (range) C(trough) (ng ml(-1)) was 11.2 (4.4-18.5) in the 180 microg week(-1) group and 16.1 (0.4-44.2) in the 270 microg week(-1) group.,Pharmacokinetics and response of obese patients with chronic hepatitis C treated with different doses of PEG-IFN alpha-2a (40KD) (PEGASYS). ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19523011/),[ng] / [ml],16.1,69454,DB00034,"Interferon Alfa-2a, Recombinant"
,9862245,terminal phase half-lives,The range of mean ribavirin terminal phase half-lives after single doses was 44-49 h.,Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9862245/),h,44-49,72811,DB00034,"Interferon Alfa-2a, Recombinant"
,9862245,washout half-lives,"The range of mean washout half-lives after week 6 was 274-298 h, reflecting release of ribavirin from deep compartment stores.",Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9862245/),h,274-298,72812,DB00034,"Interferon Alfa-2a, Recombinant"
,9862245,terminal phase half-lives,The range of single and multiple dose IFN terminal phase half-lives was 5-7 h.,Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9862245/),h,5-7,72813,DB00034,"Interferon Alfa-2a, Recombinant"
,24080649,area under the concentration-time curve from 0 to 12 h [AUC0-12]),"Despite this modification, patients with moderate and severe impairment had 12-hour (area under the concentration-time curve from 0 to 12 h [AUC0-12]) values 36% (38,452 ng · h/ml) and 25% (35,101 ng · h/ml) higher, respectively, than those with normal renal function (28,192 ng · h/ml).","Safety, tolerability, and pharmacokinetics of ribavirin in hepatitis C virus-infected patients with various degrees of renal impairment. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24080649/),[h·ng] / [ml],"38,452",81496,DB00034,"Interferon Alfa-2a, Recombinant"
,24080649,area under the concentration-time curve from 0 to 12 h [AUC0-12]),"Despite this modification, patients with moderate and severe impairment had 12-hour (area under the concentration-time curve from 0 to 12 h [AUC0-12]) values 36% (38,452 ng · h/ml) and 25% (35,101 ng · h/ml) higher, respectively, than those with normal renal function (28,192 ng · h/ml).","Safety, tolerability, and pharmacokinetics of ribavirin in hepatitis C virus-infected patients with various degrees of renal impairment. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24080649/),[h·ng] / [ml],"35,101",81497,DB00034,"Interferon Alfa-2a, Recombinant"
,24080649,area under the concentration-time curve from 0 to 12 h [AUC0-12]),"Despite this modification, patients with moderate and severe impairment had 12-hour (area under the concentration-time curve from 0 to 12 h [AUC0-12]) values 36% (38,452 ng · h/ml) and 25% (35,101 ng · h/ml) higher, respectively, than those with normal renal function (28,192 ng · h/ml).","Safety, tolerability, and pharmacokinetics of ribavirin in hepatitis C virus-infected patients with various degrees of renal impairment. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24080649/),[h·ng] / [ml],"28,192",81498,DB00034,"Interferon Alfa-2a, Recombinant"
,24080649,AUC0-12,"Patients with ESRD tolerated a 200-mg daily dose, and AUC0-12 was 20% lower (22,629 ng · h/ml) than in patients with normal renal function.","Safety, tolerability, and pharmacokinetics of ribavirin in hepatitis C virus-infected patients with various degrees of renal impairment. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24080649/),[h·ng] / [ml],"22,629",81499,DB00034,"Interferon Alfa-2a, Recombinant"
,25043197,clearance,"Lambda population pharmacokinetics was described by a one-compartment model with first-order absorption, and 33.0 L per day clearance with 47% interindividual (36% intra-individual) variability.","Derivation of Phase 3 dosing for peginterferon lambda-1a in chronic hepatitis C, Part 1: Modeling optimal treatment duration and sustained virologic response rates. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25043197/),[l] / [d],33.0,83057,DB00034,"Interferon Alfa-2a, Recombinant"
,8280722,areas under the concentration curves (AUC),"Subcutaneous administration of IFN-alpha 2 with bradykinin enhances IFN absorption via both capillaries and lymphatics, so that either the plasma or lymph areas under the concentration curves (AUC) increase significantly up to 1751 +/- 483 and 1319 +/- 608 IU/ml/min respectively as compared to the respective AUC values (613 +/- 208 and 483 +/- 213 IU/ml/min) obtained after IFN injection in normal saline.",The lymphatic route. Distribution of recombinant interferon-alpha 2 administered subcutaneously with oedematogenic drugs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8280722/),[iu] / [min·ml],1751,85812,DB00034,"Interferon Alfa-2a, Recombinant"
,8280722,areas under the concentration curves (AUC),"Subcutaneous administration of IFN-alpha 2 with bradykinin enhances IFN absorption via both capillaries and lymphatics, so that either the plasma or lymph areas under the concentration curves (AUC) increase significantly up to 1751 +/- 483 and 1319 +/- 608 IU/ml/min respectively as compared to the respective AUC values (613 +/- 208 and 483 +/- 213 IU/ml/min) obtained after IFN injection in normal saline.",The lymphatic route. Distribution of recombinant interferon-alpha 2 administered subcutaneously with oedematogenic drugs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8280722/),[iu] / [min·ml],1319,85813,DB00034,"Interferon Alfa-2a, Recombinant"
,8280722,AUC,"Subcutaneous administration of IFN-alpha 2 with bradykinin enhances IFN absorption via both capillaries and lymphatics, so that either the plasma or lymph areas under the concentration curves (AUC) increase significantly up to 1751 +/- 483 and 1319 +/- 608 IU/ml/min respectively as compared to the respective AUC values (613 +/- 208 and 483 +/- 213 IU/ml/min) obtained after IFN injection in normal saline.",The lymphatic route. Distribution of recombinant interferon-alpha 2 administered subcutaneously with oedematogenic drugs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8280722/),[iu] / [min·ml],613,85814,DB00034,"Interferon Alfa-2a, Recombinant"
,8280722,AUC,"Subcutaneous administration of IFN-alpha 2 with bradykinin enhances IFN absorption via both capillaries and lymphatics, so that either the plasma or lymph areas under the concentration curves (AUC) increase significantly up to 1751 +/- 483 and 1319 +/- 608 IU/ml/min respectively as compared to the respective AUC values (613 +/- 208 and 483 +/- 213 IU/ml/min) obtained after IFN injection in normal saline.",The lymphatic route. Distribution of recombinant interferon-alpha 2 administered subcutaneously with oedematogenic drugs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8280722/),[iu] / [min·ml],483,85815,DB00034,"Interferon Alfa-2a, Recombinant"
,18240868,viral decline,"After 4 weeks of treatment, there was a median viral decline of 2.94 log10 copies/ml in those treated with PEG-IFN-alpha2b and lamivudine and only 0.45 log10 copies/ml in the PEG-IFN-alpha2b monotherapy group.",Modelling of early viral kinetics and pegylated interferon-alpha2b pharmacokinetics in patients with HBeag-positive chronic hepatitis B. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18240868/),,2.94,85918,DB00034,"Interferon Alfa-2a, Recombinant"
,18240868,maximal,"Modelling of pharmacokinetics and viral kinetics data in this group revealed that viral load was minimal 3.6 days after PEG-IFN-alpha2b administration, the mean maximal and mean antiviral effectiveness was 70% and 48% with a mean infected cell loss rate of 0.07 per day, while no significant biphasic decline was observed.",Modelling of early viral kinetics and pegylated interferon-alpha2b pharmacokinetics in patients with HBeag-positive chronic hepatitis B. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18240868/),%,70,85919,DB00034,"Interferon Alfa-2a, Recombinant"
,18240868,anti,"Modelling of pharmacokinetics and viral kinetics data in this group revealed that viral load was minimal 3.6 days after PEG-IFN-alpha2b administration, the mean maximal and mean antiviral effectiveness was 70% and 48% with a mean infected cell loss rate of 0.07 per day, while no significant biphasic decline was observed.",Modelling of early viral kinetics and pegylated interferon-alpha2b pharmacokinetics in patients with HBeag-positive chronic hepatitis B. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18240868/),%,70,85920,DB00034,"Interferon Alfa-2a, Recombinant"
,18240868,anti,"Modelling of pharmacokinetics and viral kinetics data in this group revealed that viral load was minimal 3.6 days after PEG-IFN-alpha2b administration, the mean maximal and mean antiviral effectiveness was 70% and 48% with a mean infected cell loss rate of 0.07 per day, while no significant biphasic decline was observed.",Modelling of early viral kinetics and pegylated interferon-alpha2b pharmacokinetics in patients with HBeag-positive chronic hepatitis B. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18240868/),%,48,85921,DB00034,"Interferon Alfa-2a, Recombinant"
,18240868,infected cell loss rate,"Modelling of pharmacokinetics and viral kinetics data in this group revealed that viral load was minimal 3.6 days after PEG-IFN-alpha2b administration, the mean maximal and mean antiviral effectiveness was 70% and 48% with a mean infected cell loss rate of 0.07 per day, while no significant biphasic decline was observed.",Modelling of early viral kinetics and pegylated interferon-alpha2b pharmacokinetics in patients with HBeag-positive chronic hepatitis B. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18240868/),1/[d],0.07,85922,DB00034,"Interferon Alfa-2a, Recombinant"
,25911859,trough concentration,Mean peginterferon alfa-2a trough concentration at week 12 was 11.7±4.3 ng/mL for 180 μg and 23.4±11.3 ng/mL for 360 μg.,Induction dosing of peginterferon alfa-2a (40 KD) and/or high-dose ribavirin in genotype 1 CHC patients with difficult-to-treat characteristics: pharmacokinetic and viral kinetic (PK/VK) assessment from PROGRESS. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25911859/),[ng] / [ml],11.7,86055,DB00034,"Interferon Alfa-2a, Recombinant"
,25911859,trough concentration,Mean peginterferon alfa-2a trough concentration at week 12 was 11.7±4.3 ng/mL for 180 μg and 23.4±11.3 ng/mL for 360 μg.,Induction dosing of peginterferon alfa-2a (40 KD) and/or high-dose ribavirin in genotype 1 CHC patients with difficult-to-treat characteristics: pharmacokinetic and viral kinetic (PK/VK) assessment from PROGRESS. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25911859/),[ng] / [ml],23.4,86056,DB00034,"Interferon Alfa-2a, Recombinant"
,22858176,rate of systemic clearance,"After IV administration of PEG-IFN alfa-2a (90 μg), there was a slow decline in serum concentration, the mean rate of systemic clearance was low at 126 mL/h, and the estimated mean volume of distribution at steady state was 9 L.","Evaluation of the absolute bioavailability of pegylated interferon alfa-2a after subcutaneous administration to healthy male volunteers: an open-label, randomized, parallel-group study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22858176/),[ml] / [h],126,87925,DB00034,"Interferon Alfa-2a, Recombinant"
,22858176,volume of distribution at steady state,"After IV administration of PEG-IFN alfa-2a (90 μg), there was a slow decline in serum concentration, the mean rate of systemic clearance was low at 126 mL/h, and the estimated mean volume of distribution at steady state was 9 L.","Evaluation of the absolute bioavailability of pegylated interferon alfa-2a after subcutaneous administration to healthy male volunteers: an open-label, randomized, parallel-group study. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22858176/),l,9,87926,DB00034,"Interferon Alfa-2a, Recombinant"
,22858176,T(max),"After SC administration of PEG-IFN alfa-2a 180 μg, absorption was sustained, with mean T(max) occurring 102 hours after administration.","Evaluation of the absolute bioavailability of pegylated interferon alfa-2a after subcutaneous administration to healthy male volunteers: an open-label, randomized, parallel-group study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22858176/),h,102,87927,DB00034,"Interferon Alfa-2a, Recombinant"
,22858176,absolute bioavailability,The mean absolute bioavailability was 84%.,"Evaluation of the absolute bioavailability of pegylated interferon alfa-2a after subcutaneous administration to healthy male volunteers: an open-label, randomized, parallel-group study. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22858176/),%,84,87928,DB00034,"Interferon Alfa-2a, Recombinant"
,21098255,maximum concentration in plasma (C(max)),"The maximum concentration in plasma (C(max)) and the area under the concentration-time curve from time zero to infinity (AUC(0-∞)) were 42.8 ± 14.0 ng/ml and 16,414 ± 4,203 ng·h/ml, respectively, for healthy volunteers, while the C(max) and AUC(0-∞) were 49.9 ± 20.9 ng/ml and 18,919 ± 8,008 ng·h/ml, respectively, for ESRD patients.","Single-dose pharmacokinetics, safety, and tolerability of albinterferon alfa-2b in subjects with end-stage renal disease on hemodialysis compared to those in matched healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21098255/),[ng] / [ml],42.8,88953,DB00034,"Interferon Alfa-2a, Recombinant"
,21098255,area under the concentration-time curve from time zero to infinity (AUC(0-∞)),"The maximum concentration in plasma (C(max)) and the area under the concentration-time curve from time zero to infinity (AUC(0-∞)) were 42.8 ± 14.0 ng/ml and 16,414 ± 4,203 ng·h/ml, respectively, for healthy volunteers, while the C(max) and AUC(0-∞) were 49.9 ± 20.9 ng/ml and 18,919 ± 8,008 ng·h/ml, respectively, for ESRD patients.","Single-dose pharmacokinetics, safety, and tolerability of albinterferon alfa-2b in subjects with end-stage renal disease on hemodialysis compared to those in matched healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21098255/),[h·ng] / [ml],"16,414",88954,DB00034,"Interferon Alfa-2a, Recombinant"
,21098255,C(max),"The maximum concentration in plasma (C(max)) and the area under the concentration-time curve from time zero to infinity (AUC(0-∞)) were 42.8 ± 14.0 ng/ml and 16,414 ± 4,203 ng·h/ml, respectively, for healthy volunteers, while the C(max) and AUC(0-∞) were 49.9 ± 20.9 ng/ml and 18,919 ± 8,008 ng·h/ml, respectively, for ESRD patients.","Single-dose pharmacokinetics, safety, and tolerability of albinterferon alfa-2b in subjects with end-stage renal disease on hemodialysis compared to those in matched healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21098255/),[ng] / [ml],49.9,88955,DB00034,"Interferon Alfa-2a, Recombinant"
,21098255,AUC(0-∞),"The maximum concentration in plasma (C(max)) and the area under the concentration-time curve from time zero to infinity (AUC(0-∞)) were 42.8 ± 14.0 ng/ml and 16,414 ± 4,203 ng·h/ml, respectively, for healthy volunteers, while the C(max) and AUC(0-∞) were 49.9 ± 20.9 ng/ml and 18,919 ± 8,008 ng·h/ml, respectively, for ESRD patients.","Single-dose pharmacokinetics, safety, and tolerability of albinterferon alfa-2b in subjects with end-stage renal disease on hemodialysis compared to those in matched healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21098255/),[h·ng] / [ml],"18,919",88956,DB00034,"Interferon Alfa-2a, Recombinant"
,23975236,body surface area normalized apparent clearance,"The mean body surface area normalized apparent clearance of PEG-IFN alfa-2b was 0.56 L/h/m(2), and was similar when evaluated across the pediatric age groups.",Population pharmacokinetics of peginterferon alfa-2b in pediatric patients with chronic hepatitis C. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23975236/),[h·l] / [m(2],0.56,92176,DB00034,"Interferon Alfa-2a, Recombinant"
,11103758,Volume of distribution,Volume of distribution for both compounds was similar (approximately 1 L/kg).,"Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11103758/),[l] / [kg],1,102791,DB00034,"Interferon Alfa-2a, Recombinant"
,17501760,t(1/2),"C(max) of PEG-IFN occurred 12-48 h after the initial administration, with t(1/2) and C(min) being 49 h and 190 pg/mL, respectively.",Pharmacokinetics and enhanced PKR response in patients with chronic hepatitis C treated with pegylated interferon alpha-2b and ribavirin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17501760/),h,49,105350,DB00034,"Interferon Alfa-2a, Recombinant"
,17501760,C(min),"C(max) of PEG-IFN occurred 12-48 h after the initial administration, with t(1/2) and C(min) being 49 h and 190 pg/mL, respectively.",Pharmacokinetics and enhanced PKR response in patients with chronic hepatitis C treated with pegylated interferon alpha-2b and ribavirin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17501760/),[pg] / [ml],190,105351,DB00034,"Interferon Alfa-2a, Recombinant"
,11230473,maximum-tolerated dose,"The maximum-tolerated dose was determined as 540 microg/wk, because two patients experienced dose-limiting toxicity within 28 days of starting treatment.",Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11230473/),[μg] / [wk],540,105981,DB00034,"Interferon Alfa-2a, Recombinant"
,11230473,maximum serum concentration,"The mean maximum serum concentration increased from 5.0 to 27 ng/mL, and mean area under the curve increased from 247 to 2,981 ng/h/mL, with dose escalation from 180 microg/wk to 540 microg/wk.",Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11230473/),[ng] / [ml],5.0 to 27,105982,DB00034,"Interferon Alfa-2a, Recombinant"
,11230473,area under the curve,"The mean maximum serum concentration increased from 5.0 to 27 ng/mL, and mean area under the curve increased from 247 to 2,981 ng/h/mL, with dose escalation from 180 microg/wk to 540 microg/wk.",Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11230473/),[ng] / [h·ml],247,105983,DB00034,"Interferon Alfa-2a, Recombinant"
,9815792,clearance,5-FU clearance was higher in 14 cycles with IFN-gamma compared to the patient's prior cycle with the same doses of 5-FU/LV/IFN-alpha: 798 +/- 309 versus 601 +/- 250 ml/min/m2 (mean +/- SD; P = 0.04).,"A pilot study of gamma-1b-interferon in combination with fluorouracil, leucovorin, and alpha-2a-interferon. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815792/),[ml] / [m2·min],798,108248,DB00034,"Interferon Alfa-2a, Recombinant"
,9815792,clearance,5-FU clearance was higher in 14 cycles with IFN-gamma compared to the patient's prior cycle with the same doses of 5-FU/LV/IFN-alpha: 798 +/- 309 versus 601 +/- 250 ml/min/m2 (mean +/- SD; P = 0.04).,"A pilot study of gamma-1b-interferon in combination with fluorouracil, leucovorin, and alpha-2a-interferon. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815792/),[ml] / [m2·min],601,108249,DB00034,"Interferon Alfa-2a, Recombinant"
,9815792,clearance,"In these 28 cycles, the median 5-FU clearance was significantly lower in 11 cycles that were complicated by more severe diarrhea: 524 versus 798 ml/min/m2 (grade 2 versus 0-1; P = 0. 0032).","A pilot study of gamma-1b-interferon in combination with fluorouracil, leucovorin, and alpha-2a-interferon. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815792/),[ml] / [m2·min],524,108250,DB00034,"Interferon Alfa-2a, Recombinant"
,9815792,clearance,"In these 28 cycles, the median 5-FU clearance was significantly lower in 11 cycles that were complicated by more severe diarrhea: 524 versus 798 ml/min/m2 (grade 2 versus 0-1; P = 0. 0032).","A pilot study of gamma-1b-interferon in combination with fluorouracil, leucovorin, and alpha-2a-interferon. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815792/),[ml] / [m2·min],798,108251,DB00034,"Interferon Alfa-2a, Recombinant"
,9815792,maximum tolerated dose,"Dose reductions of IFN-gamma for chronic fatigue, malaise, or anorexia were ultimately required more frequently with >/=2.4 MU/m2 (P = 0.018), and the maximum tolerated dose of IFN-gamma was considered to be 1.2 MU/m2/ day.","A pilot study of gamma-1b-interferon in combination with fluorouracil, leucovorin, and alpha-2a-interferon. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815792/),[Mu] / [·d·m2],1.2,108252,DB00034,"Interferon Alfa-2a, Recombinant"
,21374623,relative bioavailability,"In vivo studies showed that rhIFN spherulites provided a significantly prolonged pharmacokinetics profile profile as compared with the soluble rhIFN formulation, and the relative bioavailability based on serum rhIFN levels was about 170%.","Protein spherulites for sustained release of interferon: preparation, characterization and in vivo evaluation. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21374623/),%,170,112028,DB00034,"Interferon Alfa-2a, Recombinant"
,20509027,T (max),"Peginterferon α-2b was well-absorbed following SC administration, with a median T (max) of 24 h.",Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20509027/),h,24,114159,DB00034,"Interferon Alfa-2a, Recombinant"
,20509027,half-life,Mean half-life estimates ranged from 43 to 51 h.,Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20509027/),h,43 to 51,114160,DB00034,"Interferon Alfa-2a, Recombinant"
,20509027,accumulation factor,The accumulation factor was 1.69 after induction therapy.,Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20509027/),,1.69,114161,DB00034,"Interferon Alfa-2a, Recombinant"
,17555463,maximum serum concentration,"Mean maximum serum concentration was almost doubled in patients with severe insufficiency [1305.8 pg ml(-1); 95% confidence interval (CI) 825, 1786] compared with subjects with normal renal function (731.4 pg ml(-1); 95% CI 407, 1056), whereas the apparent volume of distribution was reduced (0.80 l kg(-1)vs. 1.28 l kg(-1), respectively).",Multiple-dose pharmacokinetics of peginterferon alfa-2b in patients with renal insufficiency. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17555463/),[pg] / [ml],1305.8,115743,DB00034,"Interferon Alfa-2a, Recombinant"
,17555463,maximum serum concentration,"Mean maximum serum concentration was almost doubled in patients with severe insufficiency [1305.8 pg ml(-1); 95% confidence interval (CI) 825, 1786] compared with subjects with normal renal function (731.4 pg ml(-1); 95% CI 407, 1056), whereas the apparent volume of distribution was reduced (0.80 l kg(-1)vs. 1.28 l kg(-1), respectively).",Multiple-dose pharmacokinetics of peginterferon alfa-2b in patients with renal insufficiency. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17555463/),[pg] / [ml],731.4,115744,DB00034,"Interferon Alfa-2a, Recombinant"
,17555463,apparent volume of distribution,"Mean maximum serum concentration was almost doubled in patients with severe insufficiency [1305.8 pg ml(-1); 95% confidence interval (CI) 825, 1786] compared with subjects with normal renal function (731.4 pg ml(-1); 95% CI 407, 1056), whereas the apparent volume of distribution was reduced (0.80 l kg(-1)vs. 1.28 l kg(-1), respectively).",Multiple-dose pharmacokinetics of peginterferon alfa-2b in patients with renal insufficiency. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17555463/),[l] / [kg],0.80,115745,DB00034,"Interferon Alfa-2a, Recombinant"
,17555463,apparent volume of distribution,"Mean maximum serum concentration was almost doubled in patients with severe insufficiency [1305.8 pg ml(-1); 95% confidence interval (CI) 825, 1786] compared with subjects with normal renal function (731.4 pg ml(-1); 95% CI 407, 1056), whereas the apparent volume of distribution was reduced (0.80 l kg(-1)vs. 1.28 l kg(-1), respectively).",Multiple-dose pharmacokinetics of peginterferon alfa-2b in patients with renal insufficiency. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17555463/),[l] / [kg],1.28,115746,DB00034,"Interferon Alfa-2a, Recombinant"
,17555463,Elimination half-life,"Elimination half-life was extended in patients with moderate and severe renal insufficiency (65.6 h and 64.9 h, respectively) compared with subjects with normal renal function (51.5 h).",Multiple-dose pharmacokinetics of peginterferon alfa-2b in patients with renal insufficiency. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17555463/),h,65.6,115747,DB00034,"Interferon Alfa-2a, Recombinant"
,17555463,Elimination half-life,"Elimination half-life was extended in patients with moderate and severe renal insufficiency (65.6 h and 64.9 h, respectively) compared with subjects with normal renal function (51.5 h).",Multiple-dose pharmacokinetics of peginterferon alfa-2b in patients with renal insufficiency. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17555463/),h,64.9,115748,DB00034,"Interferon Alfa-2a, Recombinant"
,17555463,Elimination half-life,"Elimination half-life was extended in patients with moderate and severe renal insufficiency (65.6 h and 64.9 h, respectively) compared with subjects with normal renal function (51.5 h).",Multiple-dose pharmacokinetics of peginterferon alfa-2b in patients with renal insufficiency. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17555463/),h,51.5,115749,DB00034,"Interferon Alfa-2a, Recombinant"
,2141493,duration of CR,The median duration of CR is 11+ months (6-13+ months) after evaluation.,Intraperitoneal human recombinant interferon alpha-2b in minimal residual ovarian cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2141493/),month,11,121211,DB00034,"Interferon Alfa-2a, Recombinant"
,15357626,area under the curve (AUC),"Pharmacokinetic comparison by EIA did not show differences between the formulations: area under the curve (AUC) 2572 versus 2561 ng x h/L, maximum plasma concentration (Cmax) 318 versus 354 ng/L, time to Cmax (tmax) 8.2 versus 8.5 h, elimination half-life (t(1/2)) 5.87 versus 6.08 h, terminal elimination rate (lambda) 0.122 versus 0.118 h(-1), and mean residence time (MRT) 10.9 versus 12.0 h for formulations A and B, respectively.",Bioequivalence of two recombinant interferon alpha-2b liquid formulations in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15357626/),[h·ng] / [l],2572,122815,DB00034,"Interferon Alfa-2a, Recombinant"
,15357626,area under the curve (AUC),"Pharmacokinetic comparison by EIA did not show differences between the formulations: area under the curve (AUC) 2572 versus 2561 ng x h/L, maximum plasma concentration (Cmax) 318 versus 354 ng/L, time to Cmax (tmax) 8.2 versus 8.5 h, elimination half-life (t(1/2)) 5.87 versus 6.08 h, terminal elimination rate (lambda) 0.122 versus 0.118 h(-1), and mean residence time (MRT) 10.9 versus 12.0 h for formulations A and B, respectively.",Bioequivalence of two recombinant interferon alpha-2b liquid formulations in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15357626/),[h·ng] / [l],2561,122816,DB00034,"Interferon Alfa-2a, Recombinant"
,15357626,maximum plasma concentration (Cmax),"Pharmacokinetic comparison by EIA did not show differences between the formulations: area under the curve (AUC) 2572 versus 2561 ng x h/L, maximum plasma concentration (Cmax) 318 versus 354 ng/L, time to Cmax (tmax) 8.2 versus 8.5 h, elimination half-life (t(1/2)) 5.87 versus 6.08 h, terminal elimination rate (lambda) 0.122 versus 0.118 h(-1), and mean residence time (MRT) 10.9 versus 12.0 h for formulations A and B, respectively.",Bioequivalence of two recombinant interferon alpha-2b liquid formulations in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15357626/),[ng] / [l],318,122817,DB00034,"Interferon Alfa-2a, Recombinant"
,15357626,maximum plasma concentration (Cmax),"Pharmacokinetic comparison by EIA did not show differences between the formulations: area under the curve (AUC) 2572 versus 2561 ng x h/L, maximum plasma concentration (Cmax) 318 versus 354 ng/L, time to Cmax (tmax) 8.2 versus 8.5 h, elimination half-life (t(1/2)) 5.87 versus 6.08 h, terminal elimination rate (lambda) 0.122 versus 0.118 h(-1), and mean residence time (MRT) 10.9 versus 12.0 h for formulations A and B, respectively.",Bioequivalence of two recombinant interferon alpha-2b liquid formulations in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15357626/),[ng] / [l],354,122818,DB00034,"Interferon Alfa-2a, Recombinant"
,15357626,time to Cmax (tmax),"Pharmacokinetic comparison by EIA did not show differences between the formulations: area under the curve (AUC) 2572 versus 2561 ng x h/L, maximum plasma concentration (Cmax) 318 versus 354 ng/L, time to Cmax (tmax) 8.2 versus 8.5 h, elimination half-life (t(1/2)) 5.87 versus 6.08 h, terminal elimination rate (lambda) 0.122 versus 0.118 h(-1), and mean residence time (MRT) 10.9 versus 12.0 h for formulations A and B, respectively.",Bioequivalence of two recombinant interferon alpha-2b liquid formulations in healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15357626/),h,8.2,122819,DB00034,"Interferon Alfa-2a, Recombinant"
,15357626,time to Cmax (tmax),"Pharmacokinetic comparison by EIA did not show differences between the formulations: area under the curve (AUC) 2572 versus 2561 ng x h/L, maximum plasma concentration (Cmax) 318 versus 354 ng/L, time to Cmax (tmax) 8.2 versus 8.5 h, elimination half-life (t(1/2)) 5.87 versus 6.08 h, terminal elimination rate (lambda) 0.122 versus 0.118 h(-1), and mean residence time (MRT) 10.9 versus 12.0 h for formulations A and B, respectively.",Bioequivalence of two recombinant interferon alpha-2b liquid formulations in healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15357626/),h,8.5,122820,DB00034,"Interferon Alfa-2a, Recombinant"
,15357626,elimination half-life (t(1/2)),"Pharmacokinetic comparison by EIA did not show differences between the formulations: area under the curve (AUC) 2572 versus 2561 ng x h/L, maximum plasma concentration (Cmax) 318 versus 354 ng/L, time to Cmax (tmax) 8.2 versus 8.5 h, elimination half-life (t(1/2)) 5.87 versus 6.08 h, terminal elimination rate (lambda) 0.122 versus 0.118 h(-1), and mean residence time (MRT) 10.9 versus 12.0 h for formulations A and B, respectively.",Bioequivalence of two recombinant interferon alpha-2b liquid formulations in healthy male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15357626/),h,5.87,122821,DB00034,"Interferon Alfa-2a, Recombinant"
,15357626,elimination half-life (t(1/2)),"Pharmacokinetic comparison by EIA did not show differences between the formulations: area under the curve (AUC) 2572 versus 2561 ng x h/L, maximum plasma concentration (Cmax) 318 versus 354 ng/L, time to Cmax (tmax) 8.2 versus 8.5 h, elimination half-life (t(1/2)) 5.87 versus 6.08 h, terminal elimination rate (lambda) 0.122 versus 0.118 h(-1), and mean residence time (MRT) 10.9 versus 12.0 h for formulations A and B, respectively.",Bioequivalence of two recombinant interferon alpha-2b liquid formulations in healthy male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15357626/),h,6.08,122822,DB00034,"Interferon Alfa-2a, Recombinant"
,15357626,terminal elimination rate (lambda),"Pharmacokinetic comparison by EIA did not show differences between the formulations: area under the curve (AUC) 2572 versus 2561 ng x h/L, maximum plasma concentration (Cmax) 318 versus 354 ng/L, time to Cmax (tmax) 8.2 versus 8.5 h, elimination half-life (t(1/2)) 5.87 versus 6.08 h, terminal elimination rate (lambda) 0.122 versus 0.118 h(-1), and mean residence time (MRT) 10.9 versus 12.0 h for formulations A and B, respectively.",Bioequivalence of two recombinant interferon alpha-2b liquid formulations in healthy male volunteers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15357626/),1/[h],0.122,122823,DB00034,"Interferon Alfa-2a, Recombinant"
,15357626,terminal elimination rate (lambda),"Pharmacokinetic comparison by EIA did not show differences between the formulations: area under the curve (AUC) 2572 versus 2561 ng x h/L, maximum plasma concentration (Cmax) 318 versus 354 ng/L, time to Cmax (tmax) 8.2 versus 8.5 h, elimination half-life (t(1/2)) 5.87 versus 6.08 h, terminal elimination rate (lambda) 0.122 versus 0.118 h(-1), and mean residence time (MRT) 10.9 versus 12.0 h for formulations A and B, respectively.",Bioequivalence of two recombinant interferon alpha-2b liquid formulations in healthy male volunteers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15357626/),1/[h],0.118,122824,DB00034,"Interferon Alfa-2a, Recombinant"
,15357626,mean residence time (MRT),"Pharmacokinetic comparison by EIA did not show differences between the formulations: area under the curve (AUC) 2572 versus 2561 ng x h/L, maximum plasma concentration (Cmax) 318 versus 354 ng/L, time to Cmax (tmax) 8.2 versus 8.5 h, elimination half-life (t(1/2)) 5.87 versus 6.08 h, terminal elimination rate (lambda) 0.122 versus 0.118 h(-1), and mean residence time (MRT) 10.9 versus 12.0 h for formulations A and B, respectively.",Bioequivalence of two recombinant interferon alpha-2b liquid formulations in healthy male volunteers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15357626/),h,10.9,122825,DB00034,"Interferon Alfa-2a, Recombinant"
,15357626,mean residence time (MRT),"Pharmacokinetic comparison by EIA did not show differences between the formulations: area under the curve (AUC) 2572 versus 2561 ng x h/L, maximum plasma concentration (Cmax) 318 versus 354 ng/L, time to Cmax (tmax) 8.2 versus 8.5 h, elimination half-life (t(1/2)) 5.87 versus 6.08 h, terminal elimination rate (lambda) 0.122 versus 0.118 h(-1), and mean residence time (MRT) 10.9 versus 12.0 h for formulations A and B, respectively.",Bioequivalence of two recombinant interferon alpha-2b liquid formulations in healthy male volunteers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15357626/),h,12.0,122826,DB00034,"Interferon Alfa-2a, Recombinant"
,12680884,Cmax,"Increased Cmax and accumulation index of AUC(0,12 h) (median 10.5; 95% CI 6.4, 12.4), and prolonged washout half-life after multiple dosing reflected accumulation and slow clearance of ribavirin from the tissue compartments.",Pharmacokinetics of ribavirin in combined interferon-alpha 2b and ribavirin therapy for chronic hepatitis C virus infection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12680884/),,10.5,125259,DB00034,"Interferon Alfa-2a, Recombinant"
,28489678,progression-free survival,Median progression-free survival was 2.53 months [95% confidence interval (CI):1.93-3.83] and it was 1.93 months (95% CI: 1.00-3.80) in cohort 3.,Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-α2b in patients with metastatic melanoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28489678/),month,2.53,125778,DB00034,"Interferon Alfa-2a, Recombinant"
,28489678,progression-free survival,Median progression-free survival was 2.53 months [95% confidence interval (CI):1.93-3.83] and it was 1.93 months (95% CI: 1.00-3.80) in cohort 3.,Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-α2b in patients with metastatic melanoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28489678/),month,1.93,125779,DB00034,"Interferon Alfa-2a, Recombinant"
,28489678,overall survival,The median overall survival was 10.28 months (95% CI: 6.93-16.77) and 7.78 months (95% CI: 6.03-13.97) in cohort 3.,Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-α2b in patients with metastatic melanoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28489678/),month,10.28,125780,DB00034,"Interferon Alfa-2a, Recombinant"
,28489678,overall survival,The median overall survival was 10.28 months (95% CI: 6.93-16.77) and 7.78 months (95% CI: 6.03-13.97) in cohort 3.,Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-α2b in patients with metastatic melanoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28489678/),month,7.78,125781,DB00034,"Interferon Alfa-2a, Recombinant"
,28489678,response rate,"The response rate was 5.6% (95% CI: 0.68-18.7), with two patients showing an objective response (one complete response and one partial response), and the clinical benefit rate was 78% (95% CI: 61-90).",Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-α2b in patients with metastatic melanoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28489678/),%,5.6,125782,DB00034,"Interferon Alfa-2a, Recombinant"
,28489678,clinical benefit rate,"The response rate was 5.6% (95% CI: 0.68-18.7), with two patients showing an objective response (one complete response and one partial response), and the clinical benefit rate was 78% (95% CI: 61-90).",Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-α2b in patients with metastatic melanoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28489678/),%,78,125783,DB00034,"Interferon Alfa-2a, Recombinant"
,12419754,time to progression,"The median time to progression was 3.8 months, and 63% of patients were alive at 1 year.",Phase II trial of branched peginterferon-alpha 2a (40 kDa) for patients with advanced renal cell carcinoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12419754/),month,3.8,129772,DB00034,"Interferon Alfa-2a, Recombinant"
,12419754,C(max),"Serum drug levels were studied in all patients; mean C(max) at week 1 was 19 ng/ml, and levels were sustained at close to peak over 1 week.",Phase II trial of branched peginterferon-alpha 2a (40 kDa) for patients with advanced renal cell carcinoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12419754/),[ng] / [ml],19,129773,DB00034,"Interferon Alfa-2a, Recombinant"
,11034261,CL/F,Population mean CL/F estimates were 17.9 L/h (female) and 21.5 L/h (male) assuming an age of 40 years and body weight of 70 kg.,Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11034261/),[l] / [h],17.9,130818,DB00034,"Interferon Alfa-2a, Recombinant"
,11034261,CL/F,Population mean CL/F estimates were 17.9 L/h (female) and 21.5 L/h (male) assuming an age of 40 years and body weight of 70 kg.,Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11034261/),[l] / [h],21.5,130819,DB00034,"Interferon Alfa-2a, Recombinant"
,9848789,time at which Cmax occurred (Tmax),"It was found that in group B: (1) the mean maximum (SD) serum alphaIFN concentration (Cmax) was significantly higher (52 +/- 12 pg/ml) than in group A (39 +/- 12 pg/ml; P = 0.03); (2) the time at which Cmax occurred (Tmax) was significantly higher (10 +/- 3 h) than in group A (7.5 +/- 2 h; P = 0.05); (3) the observed area under the plasma alphaIFN concentration-time curve was about twice as much, i.e., 936 +/- 212 pg x h/ml, as that for group A (485 +/- 184 pg x h/ml; P < 0.0001); and (4) the alphaIFN half-life was significantly longer (9.6 +/- 2.9 h) than in group A (5.3 +/- 1.3 h).",Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9848789/),h,10,142855,DB00034,"Interferon Alfa-2a, Recombinant"
,9848789,time at which Cmax occurred (Tmax),"It was found that in group B: (1) the mean maximum (SD) serum alphaIFN concentration (Cmax) was significantly higher (52 +/- 12 pg/ml) than in group A (39 +/- 12 pg/ml; P = 0.03); (2) the time at which Cmax occurred (Tmax) was significantly higher (10 +/- 3 h) than in group A (7.5 +/- 2 h; P = 0.05); (3) the observed area under the plasma alphaIFN concentration-time curve was about twice as much, i.e., 936 +/- 212 pg x h/ml, as that for group A (485 +/- 184 pg x h/ml; P < 0.0001); and (4) the alphaIFN half-life was significantly longer (9.6 +/- 2.9 h) than in group A (5.3 +/- 1.3 h).",Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9848789/),h,7.5,142856,DB00034,"Interferon Alfa-2a, Recombinant"
,9848789,area under the plasma alphaIFN concentration-time curve,"It was found that in group B: (1) the mean maximum (SD) serum alphaIFN concentration (Cmax) was significantly higher (52 +/- 12 pg/ml) than in group A (39 +/- 12 pg/ml; P = 0.03); (2) the time at which Cmax occurred (Tmax) was significantly higher (10 +/- 3 h) than in group A (7.5 +/- 2 h; P = 0.05); (3) the observed area under the plasma alphaIFN concentration-time curve was about twice as much, i.e., 936 +/- 212 pg x h/ml, as that for group A (485 +/- 184 pg x h/ml; P < 0.0001); and (4) the alphaIFN half-life was significantly longer (9.6 +/- 2.9 h) than in group A (5.3 +/- 1.3 h).",Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9848789/),[h·pg] / [ml],936,142857,DB00034,"Interferon Alfa-2a, Recombinant"
,9848789,area under the plasma alphaIFN concentration-time curve,"It was found that in group B: (1) the mean maximum (SD) serum alphaIFN concentration (Cmax) was significantly higher (52 +/- 12 pg/ml) than in group A (39 +/- 12 pg/ml; P = 0.03); (2) the time at which Cmax occurred (Tmax) was significantly higher (10 +/- 3 h) than in group A (7.5 +/- 2 h; P = 0.05); (3) the observed area under the plasma alphaIFN concentration-time curve was about twice as much, i.e., 936 +/- 212 pg x h/ml, as that for group A (485 +/- 184 pg x h/ml; P < 0.0001); and (4) the alphaIFN half-life was significantly longer (9.6 +/- 2.9 h) than in group A (5.3 +/- 1.3 h).",Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9848789/),[h·pg] / [ml],485,142858,DB00034,"Interferon Alfa-2a, Recombinant"
,9848789,half-life,"It was found that in group B: (1) the mean maximum (SD) serum alphaIFN concentration (Cmax) was significantly higher (52 +/- 12 pg/ml) than in group A (39 +/- 12 pg/ml; P = 0.03); (2) the time at which Cmax occurred (Tmax) was significantly higher (10 +/- 3 h) than in group A (7.5 +/- 2 h; P = 0.05); (3) the observed area under the plasma alphaIFN concentration-time curve was about twice as much, i.e., 936 +/- 212 pg x h/ml, as that for group A (485 +/- 184 pg x h/ml; P < 0.0001); and (4) the alphaIFN half-life was significantly longer (9.6 +/- 2.9 h) than in group A (5.3 +/- 1.3 h).",Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9848789/),h,9.6,142859,DB00034,"Interferon Alfa-2a, Recombinant"
,9848789,half-life,"It was found that in group B: (1) the mean maximum (SD) serum alphaIFN concentration (Cmax) was significantly higher (52 +/- 12 pg/ml) than in group A (39 +/- 12 pg/ml; P = 0.03); (2) the time at which Cmax occurred (Tmax) was significantly higher (10 +/- 3 h) than in group A (7.5 +/- 2 h; P = 0.05); (3) the observed area under the plasma alphaIFN concentration-time curve was about twice as much, i.e., 936 +/- 212 pg x h/ml, as that for group A (485 +/- 184 pg x h/ml; P < 0.0001); and (4) the alphaIFN half-life was significantly longer (9.6 +/- 2.9 h) than in group A (5.3 +/- 1.3 h).",Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9848789/),h,5.3,142860,DB00034,"Interferon Alfa-2a, Recombinant"
below,9848789,trough levels,"When trough levels of alphaIFN were measured just before the 10th injection, they were always below the threshold level in the 10 patients from group A, i.e., 4.1 pg/ml, whereas in group B they were measurable for four of nine patients (P = 0.05) and ranged between 5.8 and 36.1 pg/ml.",Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9848789/),[pg] / [ml],4.1,142861,DB00034,"Interferon Alfa-2a, Recombinant"
,9848789,trough levels,"When trough levels of alphaIFN were measured just before the 10th injection, they were always below the threshold level in the 10 patients from group A, i.e., 4.1 pg/ml, whereas in group B they were measurable for four of nine patients (P = 0.05) and ranged between 5.8 and 36.1 pg/ml.",Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9848789/),[pg] / [ml],5.8 and 36.1,142862,DB00034,"Interferon Alfa-2a, Recombinant"
,14671645,serum half-life,Polyethylene glycol-modified rIFN-alpha2b is a novel formulation with a serum half-life ( approximately 40 h) compatible with once-weekly dosing.,Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14671645/),h,40,143181,DB00034,"Interferon Alfa-2a, Recombinant"
,14671645,MCR rates,The MCR rates were 23% for pegylated rIFN-alpha2b vs 28% for rIFN-alpha2b in the primary efficacy analysis and 26 vs 28% in the prospectively modified efficacy analysis.,Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14671645/),%,23,143182,DB00034,"Interferon Alfa-2a, Recombinant"
,14671645,MCR rates,The MCR rates were 23% for pegylated rIFN-alpha2b vs 28% for rIFN-alpha2b in the primary efficacy analysis and 26 vs 28% in the prospectively modified efficacy analysis.,Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14671645/),%,28,143183,DB00034,"Interferon Alfa-2a, Recombinant"
,14671645,MCR rates,The MCR rates were 23% for pegylated rIFN-alpha2b vs 28% for rIFN-alpha2b in the primary efficacy analysis and 26 vs 28% in the prospectively modified efficacy analysis.,Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14671645/),%,26,143184,DB00034,"Interferon Alfa-2a, Recombinant"
,17894655,Sustained virological response rates,"Sustained virological response rates were 38%, 30% and 18%, in the 360, 270 and 180 microg/week groups, respectively (relapse rates: 25%, 50% and 64%, respectively).",Clinical trial: pharmacodynamics and pharmacokinetics of re-treatment with fixed-dose induction of peginterferon alpha-2a in hepatitis C virus genotype 1 true non-responder patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17894655/),%,38,145815,DB00034,"Interferon Alfa-2a, Recombinant"
,17894655,Sustained virological response rates,"Sustained virological response rates were 38%, 30% and 18%, in the 360, 270 and 180 microg/week groups, respectively (relapse rates: 25%, 50% and 64%, respectively).",Clinical trial: pharmacodynamics and pharmacokinetics of re-treatment with fixed-dose induction of peginterferon alpha-2a in hepatitis C virus genotype 1 true non-responder patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17894655/),%,30,145816,DB00034,"Interferon Alfa-2a, Recombinant"
,17894655,Sustained virological response rates,"Sustained virological response rates were 38%, 30% and 18%, in the 360, 270 and 180 microg/week groups, respectively (relapse rates: 25%, 50% and 64%, respectively).",Clinical trial: pharmacodynamics and pharmacokinetics of re-treatment with fixed-dose induction of peginterferon alpha-2a in hepatitis C virus genotype 1 true non-responder patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17894655/),%,18,145817,DB00034,"Interferon Alfa-2a, Recombinant"
,17894655,relapse rates,"Sustained virological response rates were 38%, 30% and 18%, in the 360, 270 and 180 microg/week groups, respectively (relapse rates: 25%, 50% and 64%, respectively).",Clinical trial: pharmacodynamics and pharmacokinetics of re-treatment with fixed-dose induction of peginterferon alpha-2a in hepatitis C virus genotype 1 true non-responder patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17894655/),%,25,145818,DB00034,"Interferon Alfa-2a, Recombinant"
,17894655,relapse rates,"Sustained virological response rates were 38%, 30% and 18%, in the 360, 270 and 180 microg/week groups, respectively (relapse rates: 25%, 50% and 64%, respectively).",Clinical trial: pharmacodynamics and pharmacokinetics of re-treatment with fixed-dose induction of peginterferon alpha-2a in hepatitis C virus genotype 1 true non-responder patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17894655/),%,50,145819,DB00034,"Interferon Alfa-2a, Recombinant"
,17894655,relapse rates,"Sustained virological response rates were 38%, 30% and 18%, in the 360, 270 and 180 microg/week groups, respectively (relapse rates: 25%, 50% and 64%, respectively).",Clinical trial: pharmacodynamics and pharmacokinetics of re-treatment with fixed-dose induction of peginterferon alpha-2a in hepatitis C virus genotype 1 true non-responder patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17894655/),%,64,145820,DB00034,"Interferon Alfa-2a, Recombinant"
,19462475,half-life,"Pharmacokinetics studies in rats revealed that both fusion proteins had similar pharmacokinetic behavior, both with a half-life of about 50 h.",Elimination of the free sulfhydryl group in the human serum albumin (HSA) moiety of human interferon-alpha2b and HSA fusion protein increases its stability against mechanical and thermal stresses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19462475/),h,50,147328,DB00034,"Interferon Alfa-2a, Recombinant"
,23183434,absorption lag,Pharmacokinetics were best described by a two-compartment model with an 8.4-h absorption lag.,Pegylated interferon fractal pharmacokinetics: individualized dosing for hepatitis C virus infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23183434/),h,8.4,147908,DB00034,"Interferon Alfa-2a, Recombinant"
≤,23183434,area under the curve (AUC),"SVR was achieved in 36% of patients; a PEGIFN cumulative 1-week area under the curve (AUC) of ≤0.79 mg · h/liter scored highest in predicting poor response, followed by a weight of ≥93.7 kg.",Pegylated interferon fractal pharmacokinetics: individualized dosing for hepatitis C virus infection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23183434/),[h·mg] / [l],0.79,147909,DB00034,"Interferon Alfa-2a, Recombinant"
>,23183434,AUC,"Patients with a PEGIFN AUC of >0.79 mg · h/liter achieved undetectable viral load more rapidly than those with a lower AUC (hazard ratio, 1.63; 95% confidence interval, 1.21 to 2.04).",Pegylated interferon fractal pharmacokinetics: individualized dosing for hepatitis C virus infection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23183434/),[h·mg] / [l],0.79,147910,DB00034,"Interferon Alfa-2a, Recombinant"
,33725322,time to reach the median maximum serum concentration,The time to reach the median maximum serum concentration was similar between ethnicities (approximately 96-111 h).,Pharmacokinetics and Pharmacodynamics of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects After Single Subcutaneous Administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33725322/),h,96-111,153901,DB00034,"Interferon Alfa-2a, Recombinant"
,33725322,terminal half-life,The terminal half-life was 48-57 h in Japanese subjects and 31-75 h in Caucasian subjects.,Pharmacokinetics and Pharmacodynamics of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects After Single Subcutaneous Administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33725322/),h,48-57,153902,DB00034,"Interferon Alfa-2a, Recombinant"
,33725322,terminal half-life,The terminal half-life was 48-57 h in Japanese subjects and 31-75 h in Caucasian subjects.,Pharmacokinetics and Pharmacodynamics of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects After Single Subcutaneous Administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33725322/),h,31-75,153903,DB00034,"Interferon Alfa-2a, Recombinant"
,9730703,Half-lives,"Half-lives of IFN-alpha2b in hemodialysis patients were significantly longer than those in nonuremic patients (10.0 vs. 6.0 h, p < 0.05).",Interferon therapy for chronic hepatitis C in hemodialysis patients: increased serum levels of interferon. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9730703/),h,10.0,156908,DB00034,"Interferon Alfa-2a, Recombinant"
,9730703,Half-lives,"Half-lives of IFN-alpha2b in hemodialysis patients were significantly longer than those in nonuremic patients (10.0 vs. 6.0 h, p < 0.05).",Interferon therapy for chronic hepatitis C in hemodialysis patients: increased serum levels of interferon. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9730703/),h,6.0,156909,DB00034,"Interferon Alfa-2a, Recombinant"
,9730703,areas under the serum concentration curve,"Moreover, the areas under the serum concentration curve of the hemodialysis patients were significantly larger than those of nonuremic patients (756 +/- 223 vs. 324 +/- 223 IU.h/ml, p < 0.05), despite the fact that the dose of IFN-alpha administered to hemodialysis patients was half that administered to nonuremic patients.",Interferon therapy for chronic hepatitis C in hemodialysis patients: increased serum levels of interferon. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9730703/),[h·iu] / [ml],756,156910,DB00034,"Interferon Alfa-2a, Recombinant"
,9730703,areas under the serum concentration curve,"Moreover, the areas under the serum concentration curve of the hemodialysis patients were significantly larger than those of nonuremic patients (756 +/- 223 vs. 324 +/- 223 IU.h/ml, p < 0.05), despite the fact that the dose of IFN-alpha administered to hemodialysis patients was half that administered to nonuremic patients.",Interferon therapy for chronic hepatitis C in hemodialysis patients: increased serum levels of interferon. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9730703/),[h·iu] / [ml],324,156911,DB00034,"Interferon Alfa-2a, Recombinant"
,24649882,plasma concentrations,"Median (range) telaprevir plasma concentrations of TW 4, 8 and 12 were 3970 (1980-4430) ng/ml and 2520 (1870-8730) ng/ml in patients after OLT and ciclosporin- or tacrolimus-based IS, respectively, as compared to 2790 (1870-3140) in non-OLT patients (P = 0.3).",Telaprevir drug monitoring during antiviral therapy of hepatitis C graft infection after liver transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24649882/),[ng] / [ml],3970,175021,DB00034,"Interferon Alfa-2a, Recombinant"
,24649882,plasma concentrations,"Median (range) telaprevir plasma concentrations of TW 4, 8 and 12 were 3970 (1980-4430) ng/ml and 2520 (1870-8730) ng/ml in patients after OLT and ciclosporin- or tacrolimus-based IS, respectively, as compared to 2790 (1870-3140) in non-OLT patients (P = 0.3).",Telaprevir drug monitoring during antiviral therapy of hepatitis C graft infection after liver transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24649882/),[ng] / [ml],2520,175022,DB00034,"Interferon Alfa-2a, Recombinant"
,24649882,plasma concentrations,"Median (range) telaprevir plasma concentrations of TW 4, 8 and 12 were 3970 (1980-4430) ng/ml and 2520 (1870-8730) ng/ml in patients after OLT and ciclosporin- or tacrolimus-based IS, respectively, as compared to 2790 (1870-3140) in non-OLT patients (P = 0.3).",Telaprevir drug monitoring during antiviral therapy of hepatitis C graft infection after liver transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24649882/),,2790,175023,DB00034,"Interferon Alfa-2a, Recombinant"
,1557662,total compartment clearance,"The high affinity of IFN-alpha-2b to the peritoneal cavity is furthermore substantiated by the total compartment clearance, which is only about 1 1/minute for the PF in comparison to about 30 1/minute as determined for PB.",Pharmacokinetic aspects of interferon alfa-2b after intrahepatic or intraperitoneal administration. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1557662/),[1] / [min],1,178608,DB00034,"Interferon Alfa-2a, Recombinant"
,1557662,total compartment clearance,"The high affinity of IFN-alpha-2b to the peritoneal cavity is furthermore substantiated by the total compartment clearance, which is only about 1 1/minute for the PF in comparison to about 30 1/minute as determined for PB.",Pharmacokinetic aspects of interferon alfa-2b after intrahepatic or intraperitoneal administration. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1557662/),[1] / [min],30,178609,DB00034,"Interferon Alfa-2a, Recombinant"
,1557662,half life (t1/2) of elimination,IFN-alpha-2b is eliminated from the PF with a half life (t1/2) of elimination 10 to 32 hours and from the blood with t1/2 of 5 to 13 hours.,Pharmacokinetic aspects of interferon alfa-2b after intrahepatic or intraperitoneal administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1557662/),h,10 to 32,178610,DB00034,"Interferon Alfa-2a, Recombinant"
,1557662,t1/2,IFN-alpha-2b is eliminated from the PF with a half life (t1/2) of elimination 10 to 32 hours and from the blood with t1/2 of 5 to 13 hours.,Pharmacokinetic aspects of interferon alfa-2b after intrahepatic or intraperitoneal administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1557662/),h,5 to 13,178611,DB00034,"Interferon Alfa-2a, Recombinant"
below,1557662,t1/2,"After IA bolus, IFN is distributed from the blood with a t1/2 below, 2 hours, with dose-dependent serum peak concentrations (c = 47 IU for 3 MU and 145 IU for 5 MU).",Pharmacokinetic aspects of interferon alfa-2b after intrahepatic or intraperitoneal administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1557662/),h,2,178612,DB00034,"Interferon Alfa-2a, Recombinant"
,1557662,serum peak concentrations (c,"After IA bolus, IFN is distributed from the blood with a t1/2 below, 2 hours, with dose-dependent serum peak concentrations (c = 47 IU for 3 MU and 145 IU for 5 MU).",Pharmacokinetic aspects of interferon alfa-2b after intrahepatic or intraperitoneal administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1557662/),iu,47,178613,DB00034,"Interferon Alfa-2a, Recombinant"
,1557662,serum peak concentrations (c,"After IA bolus, IFN is distributed from the blood with a t1/2 below, 2 hours, with dose-dependent serum peak concentrations (c = 47 IU for 3 MU and 145 IU for 5 MU).",Pharmacokinetic aspects of interferon alfa-2b after intrahepatic or intraperitoneal administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1557662/),iu,145,178614,DB00034,"Interferon Alfa-2a, Recombinant"
,1557662,maximum concentration,"Twenty-four-hour infusion leads to a steady state within 4 to 6 hours and maximum concentration of 8.5 or 12.5 IU/mL, respectively.",Pharmacokinetic aspects of interferon alfa-2b after intrahepatic or intraperitoneal administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1557662/),[iu] / [ml],8.5,178615,DB00034,"Interferon Alfa-2a, Recombinant"
,1557662,maximum concentration,"Twenty-four-hour infusion leads to a steady state within 4 to 6 hours and maximum concentration of 8.5 or 12.5 IU/mL, respectively.",Pharmacokinetic aspects of interferon alfa-2b after intrahepatic or intraperitoneal administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1557662/),[iu] / [ml],12.5,178616,DB00034,"Interferon Alfa-2a, Recombinant"
,1557662,t1/2,During infusion IFN alpha-2b is slowly eliminated with a t1/2 of 16 hours.,Pharmacokinetic aspects of interferon alfa-2b after intrahepatic or intraperitoneal administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1557662/),h,16,178617,DB00034,"Interferon Alfa-2a, Recombinant"
,8478667,steady-state plasma concentration (Css,"Interpatient pharmacokinetics showed that rIFN-a did not alter steady-state plasma concentration (Css; range, 0.77 +/- 0.35 mumol/L to 1.85 +/- 0.48 mumol/L), elimination half-life (t1/2; mean, 9.7 +/- 4.3 minutes), area under the concentration-versus-time curve (AUC; range, 93 to 224 mumol/L x hours), total-body clearance (CI; range, 1,172 to 3,236 mL/min), or volume of distribution (range, 11.9 to 49.2 L) of FUra.",Phase I and plasma pharmacokinetic study of infusional fluorouracil combined with recombinant interferon alfa-2b in patients with advanced cancer. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8478667/),[μM] / [l],0.77,180527,DB00034,"Interferon Alfa-2a, Recombinant"
,8478667,steady-state plasma concentration (Css,"Interpatient pharmacokinetics showed that rIFN-a did not alter steady-state plasma concentration (Css; range, 0.77 +/- 0.35 mumol/L to 1.85 +/- 0.48 mumol/L), elimination half-life (t1/2; mean, 9.7 +/- 4.3 minutes), area under the concentration-versus-time curve (AUC; range, 93 to 224 mumol/L x hours), total-body clearance (CI; range, 1,172 to 3,236 mL/min), or volume of distribution (range, 11.9 to 49.2 L) of FUra.",Phase I and plasma pharmacokinetic study of infusional fluorouracil combined with recombinant interferon alfa-2b in patients with advanced cancer. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8478667/),[μM] / [l],1.85,180528,DB00034,"Interferon Alfa-2a, Recombinant"
,8478667,elimination half-life (t1/2,"Interpatient pharmacokinetics showed that rIFN-a did not alter steady-state plasma concentration (Css; range, 0.77 +/- 0.35 mumol/L to 1.85 +/- 0.48 mumol/L), elimination half-life (t1/2; mean, 9.7 +/- 4.3 minutes), area under the concentration-versus-time curve (AUC; range, 93 to 224 mumol/L x hours), total-body clearance (CI; range, 1,172 to 3,236 mL/min), or volume of distribution (range, 11.9 to 49.2 L) of FUra.",Phase I and plasma pharmacokinetic study of infusional fluorouracil combined with recombinant interferon alfa-2b in patients with advanced cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8478667/),min,9.7,180529,DB00034,"Interferon Alfa-2a, Recombinant"
,8478667,area under the concentration-versus-time curve (AUC,"Interpatient pharmacokinetics showed that rIFN-a did not alter steady-state plasma concentration (Css; range, 0.77 +/- 0.35 mumol/L to 1.85 +/- 0.48 mumol/L), elimination half-life (t1/2; mean, 9.7 +/- 4.3 minutes), area under the concentration-versus-time curve (AUC; range, 93 to 224 mumol/L x hours), total-body clearance (CI; range, 1,172 to 3,236 mL/min), or volume of distribution (range, 11.9 to 49.2 L) of FUra.",Phase I and plasma pharmacokinetic study of infusional fluorouracil combined with recombinant interferon alfa-2b in patients with advanced cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8478667/),[μM] / [h·l],93 to 224,180530,DB00034,"Interferon Alfa-2a, Recombinant"
,8478667,total-body clearance (CI,"Interpatient pharmacokinetics showed that rIFN-a did not alter steady-state plasma concentration (Css; range, 0.77 +/- 0.35 mumol/L to 1.85 +/- 0.48 mumol/L), elimination half-life (t1/2; mean, 9.7 +/- 4.3 minutes), area under the concentration-versus-time curve (AUC; range, 93 to 224 mumol/L x hours), total-body clearance (CI; range, 1,172 to 3,236 mL/min), or volume of distribution (range, 11.9 to 49.2 L) of FUra.",Phase I and plasma pharmacokinetic study of infusional fluorouracil combined with recombinant interferon alfa-2b in patients with advanced cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8478667/),[ml] / [min],"1,172 to 3,236",180531,DB00034,"Interferon Alfa-2a, Recombinant"
,8478667,volume of distribution,"Interpatient pharmacokinetics showed that rIFN-a did not alter steady-state plasma concentration (Css; range, 0.77 +/- 0.35 mumol/L to 1.85 +/- 0.48 mumol/L), elimination half-life (t1/2; mean, 9.7 +/- 4.3 minutes), area under the concentration-versus-time curve (AUC; range, 93 to 224 mumol/L x hours), total-body clearance (CI; range, 1,172 to 3,236 mL/min), or volume of distribution (range, 11.9 to 49.2 L) of FUra.",Phase I and plasma pharmacokinetic study of infusional fluorouracil combined with recombinant interferon alfa-2b in patients with advanced cancer. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8478667/),l,11.9 to 49.2,180532,DB00034,"Interferon Alfa-2a, Recombinant"
,8478667,Css,"The mean FUra Css after rIFN-a administration (1.31 mumol/L) was greater than that before rIFN-a administration (1.02 mumol/L, P < .0001).",Phase I and plasma pharmacokinetic study of infusional fluorouracil combined with recombinant interferon alfa-2b in patients with advanced cancer. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8478667/),[μM] / [l],1.31,180533,DB00034,"Interferon Alfa-2a, Recombinant"
,8478667,Css,"The mean FUra Css after rIFN-a administration (1.31 mumol/L) was greater than that before rIFN-a administration (1.02 mumol/L, P < .0001).",Phase I and plasma pharmacokinetic study of infusional fluorouracil combined with recombinant interferon alfa-2b in patients with advanced cancer. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8478667/),[μM] / [l],1.02,180534,DB00034,"Interferon Alfa-2a, Recombinant"
,27862178,Half-life (t1/2 ),"Half-life (t1/2 ) of rHSA/IFNα2a was estimated to be 120-140 h, and is potentially suitable for a dosing interval of 2 weeks or longer.","Tolerability, pharmacokinetics and antiviral activity of rHSA/IFNα2a for the treatment of chronic hepatitis B infection. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27862178/),h,120-140,185464,DB00034,"Interferon Alfa-2a, Recombinant"
,6525465,observed,"Even though individual monitoring of serum IFN titers emphasized, for a given dose, marked quantitative variations of the observed maximum concentrations, their mean values were found to be dose-dependent (358 +/- 167 U/ml at 30.10(6) U and 1044 +/- 599 U/ml at 100.10(6) U doses).",The value of a radioimmunological monitoring in cancer patients treated with interferon alpha. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6525465/),[u] / [ml],358,189478,DB00034,"Interferon Alfa-2a, Recombinant"
,6525465,maximum concentrations,"Even though individual monitoring of serum IFN titers emphasized, for a given dose, marked quantitative variations of the observed maximum concentrations, their mean values were found to be dose-dependent (358 +/- 167 U/ml at 30.10(6) U and 1044 +/- 599 U/ml at 100.10(6) U doses).",The value of a radioimmunological monitoring in cancer patients treated with interferon alpha. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6525465/),[u] / [ml],358,189479,DB00034,"Interferon Alfa-2a, Recombinant"
,6525465,maximum concentrations,"Even though individual monitoring of serum IFN titers emphasized, for a given dose, marked quantitative variations of the observed maximum concentrations, their mean values were found to be dose-dependent (358 +/- 167 U/ml at 30.10(6) U and 1044 +/- 599 U/ml at 100.10(6) U doses).",The value of a radioimmunological monitoring in cancer patients treated with interferon alpha. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6525465/),[u] / [ml],1044,189480,DB00034,"Interferon Alfa-2a, Recombinant"
,23272809,Cmax,"The average values for main parameters were: Cmax: 263 and 9.3 pg/mL; Tmax: 9.5 and 6.9 h; AUC: 4483 and 87.5 pg.h/mL, half-life (t(1/2)): 4.9 and 13.4 h; mean residence time (MRT): 13.9 and 13.5 h, for serum IFN alpha-2b and IFN gamma, respectively.",Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG) in patients with mycosis fungoides: an open-label trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23272809/),[pg] / [ml],263,190457,DB00034,"Interferon Alfa-2a, Recombinant"
,23272809,Cmax,"The average values for main parameters were: Cmax: 263 and 9.3 pg/mL; Tmax: 9.5 and 6.9 h; AUC: 4483 and 87.5 pg.h/mL, half-life (t(1/2)): 4.9 and 13.4 h; mean residence time (MRT): 13.9 and 13.5 h, for serum IFN alpha-2b and IFN gamma, respectively.",Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG) in patients with mycosis fungoides: an open-label trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23272809/),[pg] / [ml],9.3,190458,DB00034,"Interferon Alfa-2a, Recombinant"
,23272809,Tmax,"The average values for main parameters were: Cmax: 263 and 9.3 pg/mL; Tmax: 9.5 and 6.9 h; AUC: 4483 and 87.5 pg.h/mL, half-life (t(1/2)): 4.9 and 13.4 h; mean residence time (MRT): 13.9 and 13.5 h, for serum IFN alpha-2b and IFN gamma, respectively.",Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG) in patients with mycosis fungoides: an open-label trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23272809/),h,9.5,190459,DB00034,"Interferon Alfa-2a, Recombinant"
,23272809,Tmax,"The average values for main parameters were: Cmax: 263 and 9.3 pg/mL; Tmax: 9.5 and 6.9 h; AUC: 4483 and 87.5 pg.h/mL, half-life (t(1/2)): 4.9 and 13.4 h; mean residence time (MRT): 13.9 and 13.5 h, for serum IFN alpha-2b and IFN gamma, respectively.",Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG) in patients with mycosis fungoides: an open-label trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23272809/),h,6.9,190460,DB00034,"Interferon Alfa-2a, Recombinant"
,23272809,AUC,"The average values for main parameters were: Cmax: 263 and 9.3 pg/mL; Tmax: 9.5 and 6.9 h; AUC: 4483 and 87.5 pg.h/mL, half-life (t(1/2)): 4.9 and 13.4 h; mean residence time (MRT): 13.9 and 13.5 h, for serum IFN alpha-2b and IFN gamma, respectively.",Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG) in patients with mycosis fungoides: an open-label trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23272809/),[h·pg] / [ml],4483,190461,DB00034,"Interferon Alfa-2a, Recombinant"
,23272809,AUC,"The average values for main parameters were: Cmax: 263 and 9.3 pg/mL; Tmax: 9.5 and 6.9 h; AUC: 4483 and 87.5 pg.h/mL, half-life (t(1/2)): 4.9 and 13.4 h; mean residence time (MRT): 13.9 and 13.5 h, for serum IFN alpha-2b and IFN gamma, respectively.",Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG) in patients with mycosis fungoides: an open-label trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23272809/),[h·pg] / [ml],87.5,190462,DB00034,"Interferon Alfa-2a, Recombinant"
,23272809,half-life (t(1/2)),"The average values for main parameters were: Cmax: 263 and 9.3 pg/mL; Tmax: 9.5 and 6.9 h; AUC: 4483 and 87.5 pg.h/mL, half-life (t(1/2)): 4.9 and 13.4 h; mean residence time (MRT): 13.9 and 13.5 h, for serum IFN alpha-2b and IFN gamma, respectively.",Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG) in patients with mycosis fungoides: an open-label trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23272809/),h,4.9,190463,DB00034,"Interferon Alfa-2a, Recombinant"
,23272809,half-life (t(1/2)),"The average values for main parameters were: Cmax: 263 and 9.3 pg/mL; Tmax: 9.5 and 6.9 h; AUC: 4483 and 87.5 pg.h/mL, half-life (t(1/2)): 4.9 and 13.4 h; mean residence time (MRT): 13.9 and 13.5 h, for serum IFN alpha-2b and IFN gamma, respectively.",Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG) in patients with mycosis fungoides: an open-label trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23272809/),h,13.4,190464,DB00034,"Interferon Alfa-2a, Recombinant"
,23272809,mean residence time (MRT),"The average values for main parameters were: Cmax: 263 and 9.3 pg/mL; Tmax: 9.5 and 6.9 h; AUC: 4483 and 87.5 pg.h/mL, half-life (t(1/2)): 4.9 and 13.4 h; mean residence time (MRT): 13.9 and 13.5 h, for serum IFN alpha-2b and IFN gamma, respectively.",Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG) in patients with mycosis fungoides: an open-label trial. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23272809/),h,13.9,190465,DB00034,"Interferon Alfa-2a, Recombinant"
,23272809,mean residence time (MRT),"The average values for main parameters were: Cmax: 263 and 9.3 pg/mL; Tmax: 9.5 and 6.9 h; AUC: 4483 and 87.5 pg.h/mL, half-life (t(1/2)): 4.9 and 13.4 h; mean residence time (MRT): 13.9 and 13.5 h, for serum IFN alpha-2b and IFN gamma, respectively.",Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG) in patients with mycosis fungoides: an open-label trial. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23272809/),h,13.5,190466,DB00034,"Interferon Alfa-2a, Recombinant"
,6594039,terminal half-life,"Our data suggest a biphasic pattern of elimination with terminal half-life ranging from 1.9 to 2.9 hours and peak titer of 16,000 units and under for IV interferon, and terminal half-life of 6 hours with peak titers of 600 units for intramuscular interferon.",Pharmacokinetics and tolerance of intravenous and intramuscular recombinant alpha 2 interferon in patients with malignancies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6594039/),h,1.9 to 2.9,193785,DB00034,"Interferon Alfa-2a, Recombinant"
,6594039,terminal half-life,"Our data suggest a biphasic pattern of elimination with terminal half-life ranging from 1.9 to 2.9 hours and peak titer of 16,000 units and under for IV interferon, and terminal half-life of 6 hours with peak titers of 600 units for intramuscular interferon.",Pharmacokinetics and tolerance of intravenous and intramuscular recombinant alpha 2 interferon in patients with malignancies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6594039/),h,6,193786,DB00034,"Interferon Alfa-2a, Recombinant"
,6594039,peak titers,"Our data suggest a biphasic pattern of elimination with terminal half-life ranging from 1.9 to 2.9 hours and peak titer of 16,000 units and under for IV interferon, and terminal half-life of 6 hours with peak titers of 600 units for intramuscular interferon.",Pharmacokinetics and tolerance of intravenous and intramuscular recombinant alpha 2 interferon in patients with malignancies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6594039/),units,600,193787,DB00034,"Interferon Alfa-2a, Recombinant"
,34328630,Tmax,The mean Tmax of ropeginterferon alfa-2b was 92-141 h and the elimination half-life was 78-129 h.,Pharmacokinetics and Pharmacodynamics of Novel Long-Acting Ropeginterferon Alfa-2b in Healthy Chinese Subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34328630/),h,92-141,197406,DB00034,"Interferon Alfa-2a, Recombinant"
,34328630,elimination half-life,The mean Tmax of ropeginterferon alfa-2b was 92-141 h and the elimination half-life was 78-129 h.,Pharmacokinetics and Pharmacodynamics of Novel Long-Acting Ropeginterferon Alfa-2b in Healthy Chinese Subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34328630/),h,78-129,197407,DB00034,"Interferon Alfa-2a, Recombinant"
,34328630,Tmax,The mean Tmax of β2-microglobulin ranged from 118 to 132 h after a single dose of ropeginterferon alfa-2b.,Pharmacokinetics and Pharmacodynamics of Novel Long-Acting Ropeginterferon Alfa-2b in Healthy Chinese Subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34328630/),h,118 to 132,197408,DB00034,"Interferon Alfa-2a, Recombinant"
,34328630,Emax,The average Emax was 3 mcg/ml in all dose levels and the mean AUEC0-t ranged from 1608 to 1775 h/mcg/ml.,Pharmacokinetics and Pharmacodynamics of Novel Long-Acting Ropeginterferon Alfa-2b in Healthy Chinese Subjects. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34328630/),[mcg] / [ml],3,197409,DB00034,"Interferon Alfa-2a, Recombinant"
,34328630,AUEC0-t,The average Emax was 3 mcg/ml in all dose levels and the mean AUEC0-t ranged from 1608 to 1775 h/mcg/ml.,Pharmacokinetics and Pharmacodynamics of Novel Long-Acting Ropeginterferon Alfa-2b in Healthy Chinese Subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34328630/),[h] / [mcg·ml],1608 to 1775,197410,DB00034,"Interferon Alfa-2a, Recombinant"
,16761329,EC50,"Although PEG-IFN concentrations and pharmacokinetic parameters were similar in sustained virological responders (SVRs) and nonresponders (NRs), the PEG-IFN alpha-2b concentration that decreases HCV production by 50% (EC50) was lower in SVRs compared with NRs (0.04 vs. 0.45 microg/L [P = .014]).",Pharmacodynamics of PEG-IFN alpha differentiate HIV/HCV coinfected sustained virological responders from nonresponders. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16761329/),[μg] / [l],0.04,197816,DB00034,"Interferon Alfa-2a, Recombinant"
,16761329,EC50,"Although PEG-IFN concentrations and pharmacokinetic parameters were similar in sustained virological responders (SVRs) and nonresponders (NRs), the PEG-IFN alpha-2b concentration that decreases HCV production by 50% (EC50) was lower in SVRs compared with NRs (0.04 vs. 0.45 microg/L [P = .014]).",Pharmacodynamics of PEG-IFN alpha differentiate HIV/HCV coinfected sustained virological responders from nonresponders. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16761329/),[μg] / [l],0.45,197817,DB00034,"Interferon Alfa-2a, Recombinant"
,1557647,steady-state serum levels,"Mean steady-state serum levels of 5-FU at 500 mg/m2 given as a 4-hour infusion were 16.55 +/- 9.34 mumol/L and 18.23 +/- 12.77 mumol/L with and without IFN, respectively.",A phase I trial of interferon alpha-2b with folinic acid and 5-fluorouracil administered by 4-hour infusion in metastatic colorectal carcinoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1557647/),[μM] / [l],16.55,202136,DB00034,"Interferon Alfa-2a, Recombinant"
,1557647,steady-state serum levels,"Mean steady-state serum levels of 5-FU at 500 mg/m2 given as a 4-hour infusion were 16.55 +/- 9.34 mumol/L and 18.23 +/- 12.77 mumol/L with and without IFN, respectively.",A phase I trial of interferon alpha-2b with folinic acid and 5-fluorouracil administered by 4-hour infusion in metastatic colorectal carcinoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1557647/),[μM] / [l],18.23,202137,DB00034,"Interferon Alfa-2a, Recombinant"
,1557647,area under the curve,"Mean area under the curve (mumol/L x min) was 4,008 +/- 2,133 and 5,114 +/- 2,567 with and without interferon, respectively.",A phase I trial of interferon alpha-2b with folinic acid and 5-fluorouracil administered by 4-hour infusion in metastatic colorectal carcinoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1557647/),[μM] / [l·min],"4,008",202138,DB00034,"Interferon Alfa-2a, Recombinant"
,1557647,area under the curve,"Mean area under the curve (mumol/L x min) was 4,008 +/- 2,133 and 5,114 +/- 2,567 with and without interferon, respectively.",A phase I trial of interferon alpha-2b with folinic acid and 5-fluorouracil administered by 4-hour infusion in metastatic colorectal carcinoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1557647/),[μM] / [l·min],"5,114",202139,DB00034,"Interferon Alfa-2a, Recombinant"
,21145839,maximal viral load (VL),"In treatment-naïve patients, median maximal viral load (VL) reductions during 14-day monotherapy were -3.0, -3.6, -3.7, and -4.2 log(10) for the 20, 48, 120, and 240 mg groups.","Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21145839/),log(10),3.0,204539,DB00034,"Interferon Alfa-2a, Recombinant"
,21145839,maximal viral load (VL),"In treatment-naïve patients, median maximal viral load (VL) reductions during 14-day monotherapy were -3.0, -3.6, -3.7, and -4.2 log(10) for the 20, 48, 120, and 240 mg groups.","Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21145839/),log(10),3.6,204540,DB00034,"Interferon Alfa-2a, Recombinant"
,21145839,maximal viral load (VL),"In treatment-naïve patients, median maximal viral load (VL) reductions during 14-day monotherapy were -3.0, -3.6, -3.7, and -4.2 log(10) for the 20, 48, 120, and 240 mg groups.","Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21145839/),log(10),3.7,204541,DB00034,"Interferon Alfa-2a, Recombinant"
<,21145839,VL,"In treatment-experienced patients, treatment with BI201335 and PegIFN/RBV achieved VL<25 IU/ml at Day 28 in 3/6, 4/7, and 5/6 patients in the 48, 120, and 240 mg dose groups.","Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21145839/),[iu] / [ml],25,204542,DB00034,"Interferon Alfa-2a, Recombinant"
,8269608,capture efficiency,The capture efficiency was 51% +/- 13% and the release half-life in human plasma at 37 degrees C was 16 days.,Pharmacokinetics of an extended-release human interferon alpha-2b formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8269608/),%,51,206053,DB00034,"Interferon Alfa-2a, Recombinant"
,8269608,release half-life,The capture efficiency was 51% +/- 13% and the release half-life in human plasma at 37 degrees C was 16 days.,Pharmacokinetics of an extended-release human interferon alpha-2b formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8269608/),d,16,206054,DB00034,"Interferon Alfa-2a, Recombinant"
,8269608,half-life,Depo/IFN exhibited a 13-fold longer intraperitoneal (i.p.) half-life as compared with Std/IFN (20 vs 1.5 h).,Pharmacokinetics of an extended-release human interferon alpha-2b formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8269608/),h,20,206055,DB00034,"Interferon Alfa-2a, Recombinant"
,8269608,half-life,Depo/IFN exhibited a 13-fold longer intraperitoneal (i.p.) half-life as compared with Std/IFN (20 vs 1.5 h).,Pharmacokinetics of an extended-release human interferon alpha-2b formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8269608/),h,1.5,206056,DB00034,"Interferon Alfa-2a, Recombinant"
,7917928,Michaelis constant (KM),"With the Michaelis constant (KM) set at 15 microM, values were derived for the volume of distribution (Vd), the maximum rate of non-linear elimination (Vmax) and the first-order elimination rate constant (K1.e).",Lack of effect of interferon alpha 2a upon fluorouracil pharmacokinetics. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7917928/),μM,15,208699,DB00034,"Interferon Alfa-2a, Recombinant"
,7917928,Vd,"Mean (+/- s.d.) values in control (no IFN-alpha) patients were: Vd 10.4 (+/- 1.9) l m-2, Vmax 182 (+/- 59) mumol l-1 h-1 and k1.e 4.35 (+/- 0.58) h-1.",Lack of effect of interferon alpha 2a upon fluorouracil pharmacokinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7917928/),[l] / [(m)^2],10.4,208700,DB00034,"Interferon Alfa-2a, Recombinant"
,7917928,Vmax,"Mean (+/- s.d.) values in control (no IFN-alpha) patients were: Vd 10.4 (+/- 1.9) l m-2, Vmax 182 (+/- 59) mumol l-1 h-1 and k1.e 4.35 (+/- 0.58) h-1.",Lack of effect of interferon alpha 2a upon fluorouracil pharmacokinetics. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7917928/),[μM] / [h·l],182,208701,DB00034,"Interferon Alfa-2a, Recombinant"
,7917928,k1.e,"Mean (+/- s.d.) values in control (no IFN-alpha) patients were: Vd 10.4 (+/- 1.9) l m-2, Vmax 182 (+/- 59) mumol l-1 h-1 and k1.e 4.35 (+/- 0.58) h-1.",Lack of effect of interferon alpha 2a upon fluorouracil pharmacokinetics. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7917928/),1/[h],4.35,208702,DB00034,"Interferon Alfa-2a, Recombinant"
,7917928,Vd,"No significant differences were detected in patients receiving IFN-alpha, in whom the equivalent mean values were Vd 10.0 (+/- 0.9) l m-2, Vmax 141 (+/- 27) mumol l-1 h-1 and k1.e 3.96 (+/- 0.5) h-1.",Lack of effect of interferon alpha 2a upon fluorouracil pharmacokinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7917928/),[l] / [(m)^2],10.0,208703,DB00034,"Interferon Alfa-2a, Recombinant"
,7917928,Vmax,"No significant differences were detected in patients receiving IFN-alpha, in whom the equivalent mean values were Vd 10.0 (+/- 0.9) l m-2, Vmax 141 (+/- 27) mumol l-1 h-1 and k1.e 3.96 (+/- 0.5) h-1.",Lack of effect of interferon alpha 2a upon fluorouracil pharmacokinetics. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7917928/),[μM] / [h·l],141,208704,DB00034,"Interferon Alfa-2a, Recombinant"
,7917928,k1.e,"No significant differences were detected in patients receiving IFN-alpha, in whom the equivalent mean values were Vd 10.0 (+/- 0.9) l m-2, Vmax 141 (+/- 27) mumol l-1 h-1 and k1.e 3.96 (+/- 0.5) h-1.",Lack of effect of interferon alpha 2a upon fluorouracil pharmacokinetics. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7917928/),1/[h],3.96,208705,DB00034,"Interferon Alfa-2a, Recombinant"
,7917928,AUC0-22 h,"Mean trapezoidal AUC0-22 h was similar in the two groups (control patients 116 microM h, IFN-alpha patients 125 microM h).",Lack of effect of interferon alpha 2a upon fluorouracil pharmacokinetics. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7917928/),h·μM,116,208706,DB00034,"Interferon Alfa-2a, Recombinant"
,7917928,AUC0-22 h,"Mean trapezoidal AUC0-22 h was similar in the two groups (control patients 116 microM h, IFN-alpha patients 125 microM h).",Lack of effect of interferon alpha 2a upon fluorouracil pharmacokinetics. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7917928/),h·μM,125,208707,DB00034,"Interferon Alfa-2a, Recombinant"
,18178958,overall response rate,"In all, 116 patients were assessable for response: 2 (1.7%) had a complete response and 19 (16.4%) a partial response (overall response rate 18.1%).",Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18178958/),%,18.1,210574,DB00034,"Interferon Alfa-2a, Recombinant"
,18178958,Overall survival,Overall survival was 9.4 months; PFS was 2.8 months.,Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18178958/),month,9.4,210575,DB00034,"Interferon Alfa-2a, Recombinant"
,18178958,PFS,Overall survival was 9.4 months; PFS was 2.8 months.,Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18178958/),month,2.8,210576,DB00034,"Interferon Alfa-2a, Recombinant"
,9815842,whole blood residence time,"For group 1 patients, whole blood residence time increased significantly between that predicted from the tracer doses and therapy doses (42.6 +/- 4.7 versus 51.5 +/- 4.8 h, respectively; P < 0.01).","Effect of recombinant alpha-interferon on pharmacokinetics, biodistribution, toxicity, and efficacy of 131I-labeled monoclonal antibody CC49 in breast cancer: a phase II trial. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815842/),h,42.6,211315,DB00034,"Interferon Alfa-2a, Recombinant"
,9815842,whole blood residence time,"For group 1 patients, whole blood residence time increased significantly between that predicted from the tracer doses and therapy doses (42.6 +/- 4.7 versus 51.5 +/- 4.8 h, respectively; P < 0.01).","Effect of recombinant alpha-interferon on pharmacokinetics, biodistribution, toxicity, and efficacy of 131I-labeled monoclonal antibody CC49 in breast cancer: a phase II trial. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815842/),h,51.5,211316,DB00034,"Interferon Alfa-2a, Recombinant"
,9815842,radiation absorbed dose,The calculated radiation absorbed dose to red marrow from therapy compared to tracer activity was also significantly higher for this group (1.25 +/- 0.35 versus 1. 07 +/- 0.26 cGy/mCi; P < 0.05).,"Effect of recombinant alpha-interferon on pharmacokinetics, biodistribution, toxicity, and efficacy of 131I-labeled monoclonal antibody CC49 in breast cancer: a phase II trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815842/),[cgy] / [mci],1.25,211317,DB00034,"Interferon Alfa-2a, Recombinant"
,9815842,radiation absorbed dose,The calculated radiation absorbed dose to red marrow from therapy compared to tracer activity was also significantly higher for this group (1.25 +/- 0.35 versus 1. 07 +/- 0.26 cGy/mCi; P < 0.05).,"Effect of recombinant alpha-interferon on pharmacokinetics, biodistribution, toxicity, and efficacy of 131I-labeled monoclonal antibody CC49 in breast cancer: a phase II trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815842/),[cgy] / [mci],1. 07,211318,DB00034,"Interferon Alfa-2a, Recombinant"
,24602156,RVR,"Among non-CC genotype patients, RVR rates were 26.5% (14.6-43.1%), 52.3% (43.0-61.3%) and 5.7% (2.2-13.8%), and cEVR rates were 76.5% (60.0-87.6%), 84.6% (76.6-90.1%) and 28.6% (19.3-40.1%), respectively.",Understanding the effect of the HCV polymerase inhibitor mericitabine on early viral kinetics in the phase 2 JUMP-C and PROPEL studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24602156/),%,26,214067,DB00034,"Interferon Alfa-2a, Recombinant"
,24602156,RVR,"Among non-CC genotype patients, RVR rates were 26.5% (14.6-43.1%), 52.3% (43.0-61.3%) and 5.7% (2.2-13.8%), and cEVR rates were 76.5% (60.0-87.6%), 84.6% (76.6-90.1%) and 28.6% (19.3-40.1%), respectively.",Understanding the effect of the HCV polymerase inhibitor mericitabine on early viral kinetics in the phase 2 JUMP-C and PROPEL studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24602156/),%,52,214068,DB00034,"Interferon Alfa-2a, Recombinant"
,24602156,cEVR,"Among non-CC genotype patients, RVR rates were 26.5% (14.6-43.1%), 52.3% (43.0-61.3%) and 5.7% (2.2-13.8%), and cEVR rates were 76.5% (60.0-87.6%), 84.6% (76.6-90.1%) and 28.6% (19.3-40.1%), respectively.",Understanding the effect of the HCV polymerase inhibitor mericitabine on early viral kinetics in the phase 2 JUMP-C and PROPEL studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24602156/),%,76.,214069,DB00034,"Interferon Alfa-2a, Recombinant"
,24602156,cEVR,"Among non-CC genotype patients, RVR rates were 26.5% (14.6-43.1%), 52.3% (43.0-61.3%) and 5.7% (2.2-13.8%), and cEVR rates were 76.5% (60.0-87.6%), 84.6% (76.6-90.1%) and 28.6% (19.3-40.1%), respectively.",Understanding the effect of the HCV polymerase inhibitor mericitabine on early viral kinetics in the phase 2 JUMP-C and PROPEL studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24602156/),%,84.6,214070,DB00034,"Interferon Alfa-2a, Recombinant"
,24602156,cEVR,"Among non-CC genotype patients, RVR rates were 26.5% (14.6-43.1%), 52.3% (43.0-61.3%) and 5.7% (2.2-13.8%), and cEVR rates were 76.5% (60.0-87.6%), 84.6% (76.6-90.1%) and 28.6% (19.3-40.1%), respectively.",Understanding the effect of the HCV polymerase inhibitor mericitabine on early viral kinetics in the phase 2 JUMP-C and PROPEL studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24602156/),%,28.6,214071,DB00034,"Interferon Alfa-2a, Recombinant"
,15735615,accumulation ratios,"The mean accumulation ratios (week 4/first dose) for C(max) and AUC from time 0 to 168 hours of peginterferon alfa-2a were 2.1 and 2.3, respectively.",Peginterferon alfa-2a does not alter the pharmacokinetics of methadone in patients with chronic hepatitis C undergoing methadone maintenance therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15735615/),,2.1,215717,DB00034,"Interferon Alfa-2a, Recombinant"
,15735615,accumulation ratios,"The mean accumulation ratios (week 4/first dose) for C(max) and AUC from time 0 to 168 hours of peginterferon alfa-2a were 2.1 and 2.3, respectively.",Peginterferon alfa-2a does not alter the pharmacokinetics of methadone in patients with chronic hepatitis C undergoing methadone maintenance therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15735615/),,2.3,215718,DB00034,"Interferon Alfa-2a, Recombinant"
,2281675,t1/2 el,IFN is eliminated from the PF with t1/2 el = 10-32h and from the blood with t1/2 el = 5-13h.,[Pharmacokinetic aspects of dosage increase of recombinant interferon alpha-2B in patients following intraperitoneal and intra-arterial application]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2281675/),h,10-32,229485,DB00034,"Interferon Alfa-2a, Recombinant"
,2281675,t1/2 el,IFN is eliminated from the PF with t1/2 el = 10-32h and from the blood with t1/2 el = 5-13h.,[Pharmacokinetic aspects of dosage increase of recombinant interferon alpha-2B in patients following intraperitoneal and intra-arterial application]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2281675/),h,5-13,229486,DB00034,"Interferon Alfa-2a, Recombinant"
below,2281675,half-life,After an i.a. bolus at either dosage IFN is distributed from the blood with a half-life of below 2h.,[Pharmacokinetic aspects of dosage increase of recombinant interferon alpha-2B in patients following intraperitoneal and intra-arterial application]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2281675/),h,2,229487,DB00034,"Interferon Alfa-2a, Recombinant"
,2281675,cmax,"24h infusion leads to a steady-state within 4-6h and a cmax of 8.5 or 12.5 units/ml, respectively.",[Pharmacokinetic aspects of dosage increase of recombinant interferon alpha-2B in patients following intraperitoneal and intra-arterial application]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2281675/),[units] / [ml],8.5,229488,DB00034,"Interferon Alfa-2a, Recombinant"
,2281675,cmax,"24h infusion leads to a steady-state within 4-6h and a cmax of 8.5 or 12.5 units/ml, respectively.",[Pharmacokinetic aspects of dosage increase of recombinant interferon alpha-2B in patients following intraperitoneal and intra-arterial application]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2281675/),[units] / [ml],12.5,229489,DB00034,"Interferon Alfa-2a, Recombinant"
,2281675,t1/2 el,IFN is slowly eliminated during infusion with a t1/2 el of 16h.,[Pharmacokinetic aspects of dosage increase of recombinant interferon alpha-2B in patients following intraperitoneal and intra-arterial application]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2281675/),h,16,229490,DB00034,"Interferon Alfa-2a, Recombinant"
,21092287,AUC,"In spite of a high subject variability, the parameters' mean were very close (in all cases p > 0.05): AUC: 53623 vs. 44311 pg.h/mL; Cmax: 333 vs. 271 pg/mL; Tmax: 54 vs. 55 h; half-life (t1/2): 72.4 vs.","Pharmacokinetic and pharmacodynamic comparison of two ""pegylated"" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21092287/),[h·pg] / [ml],53623,235787,DB00034,"Interferon Alfa-2a, Recombinant"
,21092287,AUC,"In spite of a high subject variability, the parameters' mean were very close (in all cases p > 0.05): AUC: 53623 vs. 44311 pg.h/mL; Cmax: 333 vs. 271 pg/mL; Tmax: 54 vs. 55 h; half-life (t1/2): 72.4 vs.","Pharmacokinetic and pharmacodynamic comparison of two ""pegylated"" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21092287/),[h·pg] / [ml],44311,235788,DB00034,"Interferon Alfa-2a, Recombinant"
,21092287,Cmax,"In spite of a high subject variability, the parameters' mean were very close (in all cases p > 0.05): AUC: 53623 vs. 44311 pg.h/mL; Cmax: 333 vs. 271 pg/mL; Tmax: 54 vs. 55 h; half-life (t1/2): 72.4 vs.","Pharmacokinetic and pharmacodynamic comparison of two ""pegylated"" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21092287/),[pg] / [ml],333,235789,DB00034,"Interferon Alfa-2a, Recombinant"
,21092287,Cmax,"In spite of a high subject variability, the parameters' mean were very close (in all cases p > 0.05): AUC: 53623 vs. 44311 pg.h/mL; Cmax: 333 vs. 271 pg/mL; Tmax: 54 vs. 55 h; half-life (t1/2): 72.4 vs.","Pharmacokinetic and pharmacodynamic comparison of two ""pegylated"" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21092287/),[pg] / [ml],271,235790,DB00034,"Interferon Alfa-2a, Recombinant"
,21092287,Tmax,"In spite of a high subject variability, the parameters' mean were very close (in all cases p > 0.05): AUC: 53623 vs. 44311 pg.h/mL; Cmax: 333 vs. 271 pg/mL; Tmax: 54 vs. 55 h; half-life (t1/2): 72.4 vs.","Pharmacokinetic and pharmacodynamic comparison of two ""pegylated"" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21092287/),h,54,235791,DB00034,"Interferon Alfa-2a, Recombinant"
,21092287,Tmax,"In spite of a high subject variability, the parameters' mean were very close (in all cases p > 0.05): AUC: 53623 vs. 44311 pg.h/mL; Cmax: 333 vs. 271 pg/mL; Tmax: 54 vs. 55 h; half-life (t1/2): 72.4 vs.","Pharmacokinetic and pharmacodynamic comparison of two ""pegylated"" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21092287/),h,55,235792,DB00034,"Interferon Alfa-2a, Recombinant"
,21092287,half-life (t1/2),"In spite of a high subject variability, the parameters' mean were very close (in all cases p > 0.05): AUC: 53623 vs. 44311 pg.h/mL; Cmax: 333 vs. 271 pg/mL; Tmax: 54 vs. 55 h; half-life (t1/2): 72.4 vs.","Pharmacokinetic and pharmacodynamic comparison of two ""pegylated"" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21092287/),,72.4,235793,DB00034,"Interferon Alfa-2a, Recombinant"
,21092287,terminal elimination rate (lambda),64.8 h; terminal elimination rate (lambda): 0.011 vs. 0.014 h(-1); mean residence time (MRT): 135 vs.,"Pharmacokinetic and pharmacodynamic comparison of two ""pegylated"" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21092287/),1/[h],0.011,235794,DB00034,"Interferon Alfa-2a, Recombinant"
,21092287,terminal elimination rate (lambda),64.8 h; terminal elimination rate (lambda): 0.011 vs. 0.014 h(-1); mean residence time (MRT): 135 vs.,"Pharmacokinetic and pharmacodynamic comparison of two ""pegylated"" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21092287/),1/[h],0.014,235795,DB00034,"Interferon Alfa-2a, Recombinant"
,21092287,mean residence time (MRT),64.8 h; terminal elimination rate (lambda): 0.011 vs. 0.014 h(-1); mean residence time (MRT): 135 vs.,"Pharmacokinetic and pharmacodynamic comparison of two ""pegylated"" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21092287/),,135,235796,DB00034,"Interferon Alfa-2a, Recombinant"
,20923249,terminal elimination half-life,The only statistically significant difference we observed was a significant reduction in the terminal elimination half-life of fluoxetine (from 47.30 to 33.23 hours; p = 0.014) after peginterferon-α-2b treatment.,Fluoxetine disposition in patients with chronic hepatitis C treated with interferon-α. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20923249/),h,47.30,238596,DB00034,"Interferon Alfa-2a, Recombinant"
,20923249,terminal elimination half-life,The only statistically significant difference we observed was a significant reduction in the terminal elimination half-life of fluoxetine (from 47.30 to 33.23 hours; p = 0.014) after peginterferon-α-2b treatment.,Fluoxetine disposition in patients with chronic hepatitis C treated with interferon-α. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20923249/),h,33.23,238597,DB00034,"Interferon Alfa-2a, Recombinant"
,26467418,peak serum IFN level,"The peak serum IFN level, maximum drug concentration (Cmax), and the time to reach maximum concentration (Tmax), were 11.58 ± ng/ml and 40 min, respectively, for high-dose MNs group.",Dissolving microneedle-based intradermal delivery of interferon-α-2b. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26467418/),[ng] / [ml],11.58,242169,DB00034,"Interferon Alfa-2a, Recombinant"
,26467418,time to reach maximum concentration (Tmax),"The peak serum IFN level, maximum drug concentration (Cmax), and the time to reach maximum concentration (Tmax), were 11.58 ± ng/ml and 40 min, respectively, for high-dose MNs group.",Dissolving microneedle-based intradermal delivery of interferon-α-2b. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26467418/),min,40,242170,DB00034,"Interferon Alfa-2a, Recombinant"
,26467418,area under the curve (AUC),"The area under the curve (AUC) of MNs group was 28.85 ng·h/ml, while intramuscular injection (IM) group with equal dose was 31.17 ng·h/ml.",Dissolving microneedle-based intradermal delivery of interferon-α-2b. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26467418/),[h·ng] / [ml],28.85,242171,DB00034,"Interferon Alfa-2a, Recombinant"
,26467418,area under the curve (AUC),"The area under the curve (AUC) of MNs group was 28.85 ng·h/ml, while intramuscular injection (IM) group with equal dose was 31.17 ng·h/ml.",Dissolving microneedle-based intradermal delivery of interferon-α-2b. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26467418/),[h·ng] / [ml],31.17,242172,DB00034,"Interferon Alfa-2a, Recombinant"
,8862717,maximum tolerated dose,The maximum tolerated dose of IFN was 18 MU/m2.,"A phase I trial of 5-fluorouracil, leucovorin and interferon-alpha 2b administered by 24 h infusion in metastatic colorectal carcinoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8862717/),[Mu] / [m2],18,246204,DB00034,"Interferon Alfa-2a, Recombinant"
,8983929,percentage AUC-ratios,"The extent of biotransformation of CHO-THFA into CH3-THFA, which takes place in the blood, is not influenced by IFN because percentage AUC-ratios CHO-THFA:CH3-THFA were 89.5:10.5% for the control group and 88.8:11.2% for the IFN group.",Disposition of 5-formyl- and 5-methyltetrahydrofolic acid in serum after i.v. bolus of calcium folinate: pharmacokinetic drug interaction with preadministered interferon-alpha-2b. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983929/),%,89.5,250515,DB00034,"Interferon Alfa-2a, Recombinant"
,8983929,percentage AUC-ratios,"The extent of biotransformation of CHO-THFA into CH3-THFA, which takes place in the blood, is not influenced by IFN because percentage AUC-ratios CHO-THFA:CH3-THFA were 89.5:10.5% for the control group and 88.8:11.2% for the IFN group.",Disposition of 5-formyl- and 5-methyltetrahydrofolic acid in serum after i.v. bolus of calcium folinate: pharmacokinetic drug interaction with preadministered interferon-alpha-2b. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983929/),%,10.5,250516,DB00034,"Interferon Alfa-2a, Recombinant"
,8983929,percentage AUC-ratios,"The extent of biotransformation of CHO-THFA into CH3-THFA, which takes place in the blood, is not influenced by IFN because percentage AUC-ratios CHO-THFA:CH3-THFA were 89.5:10.5% for the control group and 88.8:11.2% for the IFN group.",Disposition of 5-formyl- and 5-methyltetrahydrofolic acid in serum after i.v. bolus of calcium folinate: pharmacokinetic drug interaction with preadministered interferon-alpha-2b. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983929/),%,88.8,250517,DB00034,"Interferon Alfa-2a, Recombinant"
,12934165,absorption half-life,"The absorption half-life of standard interferon alfa is 2.3 hours, while absorption half-lives for peginterferon alfa-2a and alfa-2b are 50 hours and 4.6 hours, respectively.",Pharmacokinetics of peginterferons. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12934165/),h,2.3,262256,DB00034,"Interferon Alfa-2a, Recombinant"
,12934165,absorption half-lives,"The absorption half-life of standard interferon alfa is 2.3 hours, while absorption half-lives for peginterferon alfa-2a and alfa-2b are 50 hours and 4.6 hours, respectively.",Pharmacokinetics of peginterferons. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12934165/),h,50,262257,DB00034,"Interferon Alfa-2a, Recombinant"
,12934165,absorption half-lives,"The absorption half-life of standard interferon alfa is 2.3 hours, while absorption half-lives for peginterferon alfa-2a and alfa-2b are 50 hours and 4.6 hours, respectively.",Pharmacokinetics of peginterferons. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12934165/),h,4.6,262258,DB00034,"Interferon Alfa-2a, Recombinant"
,7651979,AUC-,"Mean AUC-values increase from 5454 ng/ml.h (day 1) to 12069 ng/ml.h (day 3, p < 0.05) and subsequently to 14919 ng/ml.h on day 5 (p < 0.005).",[Drug interactions between interferon alpha 2b and 5-fluorouracil during continuous intravenous 5FU infusion]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7651979/),[ng] / [h·ml],5454,263542,DB00034,"Interferon Alfa-2a, Recombinant"
,7651979,AUC-,"Mean AUC-values increase from 5454 ng/ml.h (day 1) to 12069 ng/ml.h (day 3, p < 0.05) and subsequently to 14919 ng/ml.h on day 5 (p < 0.005).",[Drug interactions between interferon alpha 2b and 5-fluorouracil during continuous intravenous 5FU infusion]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7651979/),[ng] / [h·ml],12069,263543,DB00034,"Interferon Alfa-2a, Recombinant"
,7651979,AUC-,"Mean AUC-values increase from 5454 ng/ml.h (day 1) to 12069 ng/ml.h (day 3, p < 0.05) and subsequently to 14919 ng/ml.h on day 5 (p < 0.005).",[Drug interactions between interferon alpha 2b and 5-fluorouracil during continuous intravenous 5FU infusion]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7651979/),[ng] / [h·ml],14919,263544,DB00034,"Interferon Alfa-2a, Recombinant"
,7651979,total body clearance,"IFN causes an decrease of the total body clearance from 2949 ml/h (day 1) to 1959 ml/h on day 3 and to 1258 ml/h on day 5 (p < 0.008), respectively.",[Drug interactions between interferon alpha 2b and 5-fluorouracil during continuous intravenous 5FU infusion]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7651979/),[ml] / [h],2949,263545,DB00034,"Interferon Alfa-2a, Recombinant"
,7651979,total body clearance,"IFN causes an decrease of the total body clearance from 2949 ml/h (day 1) to 1959 ml/h on day 3 and to 1258 ml/h on day 5 (p < 0.008), respectively.",[Drug interactions between interferon alpha 2b and 5-fluorouracil during continuous intravenous 5FU infusion]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7651979/),[ml] / [h],1959,263546,DB00034,"Interferon Alfa-2a, Recombinant"
,7651979,total body clearance,"IFN causes an decrease of the total body clearance from 2949 ml/h (day 1) to 1959 ml/h on day 3 and to 1258 ml/h on day 5 (p < 0.008), respectively.",[Drug interactions between interferon alpha 2b and 5-fluorouracil during continuous intravenous 5FU infusion]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7651979/),[ml] / [h],1258,263547,DB00034,"Interferon Alfa-2a, Recombinant"
,15274364,survival time,The median survival time was 11.3 (2.5-45) months.,"Combined treatment with histamine dihydrochloride, interleukin-2 and interferon-alpha in patients with metastatic melanoma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15274364/),month,11.3,265823,DB00034,"Interferon Alfa-2a, Recombinant"
,1919632,overall response rate,"In 22 patients without prior 5-FU therapy, three complete (13.6%) and seven partial (31.8%) responses were seen, for an overall response rate of 45.4% (95% confidence interval, 24.4% to 67.8%).",A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1919632/),%,45.4,269680,DB00034,"Interferon Alfa-2a, Recombinant"
,25801095,maximum decline,Intravenous administration of pegylated interferon resulted in a stronger and faster decline in HCV RNA than subcutaneous administration with a maximum decline of 1.17 log10 vs. 0.41 log10 or 1.32 log10 vs.,Improved pharmacodynamics and pharmacokinetics after i.v. application of peginterferon alfa-2a in hepatitis C null responders. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25801095/),log10,1.17,269870,DB00034,"Interferon Alfa-2a, Recombinant"
,25801095,maximum decline,Intravenous administration of pegylated interferon resulted in a stronger and faster decline in HCV RNA than subcutaneous administration with a maximum decline of 1.17 log10 vs. 0.41 log10 or 1.32 log10 vs.,Improved pharmacodynamics and pharmacokinetics after i.v. application of peginterferon alfa-2a in hepatitis C null responders. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25801095/),log10,0.41,269871,DB00034,"Interferon Alfa-2a, Recombinant"
,25801095,maximum decline,Intravenous administration of pegylated interferon resulted in a stronger and faster decline in HCV RNA than subcutaneous administration with a maximum decline of 1.17 log10 vs. 0.41 log10 or 1.32 log10 vs.,Improved pharmacodynamics and pharmacokinetics after i.v. application of peginterferon alfa-2a in hepatitis C null responders. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25801095/),log10,1.32,269872,DB00034,"Interferon Alfa-2a, Recombinant"
,9363862,area under the concentration-time curve (AUC),"Following 30-mg/m2 doses, the ATRA area under the concentration-time curve (AUC) decreased from 96 +/- 14 micromol/L/min on day 1 to 26 +/- 24 micromol/L/min by day 3 of drug administration, but on day 1 of the fourth consecutive week of therapy, the AUC averaged 110 +/- 16 micromol/L/min.",Phase I trial and pharmacokinetic study of all-trans-retinoic acid administered on an intermittent schedule in combination with interferon-alpha2a in pediatric patients with refractory cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9363862/),[μM] / [l·min],96,270798,DB00034,"Interferon Alfa-2a, Recombinant"
,9363862,area under the concentration-time curve (AUC),"Following 30-mg/m2 doses, the ATRA area under the concentration-time curve (AUC) decreased from 96 +/- 14 micromol/L/min on day 1 to 26 +/- 24 micromol/L/min by day 3 of drug administration, but on day 1 of the fourth consecutive week of therapy, the AUC averaged 110 +/- 16 micromol/L/min.",Phase I trial and pharmacokinetic study of all-trans-retinoic acid administered on an intermittent schedule in combination with interferon-alpha2a in pediatric patients with refractory cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9363862/),[μM] / [l·min],26,270799,DB00034,"Interferon Alfa-2a, Recombinant"
,9363862,AUC,"Following 30-mg/m2 doses, the ATRA area under the concentration-time curve (AUC) decreased from 96 +/- 14 micromol/L/min on day 1 to 26 +/- 24 micromol/L/min by day 3 of drug administration, but on day 1 of the fourth consecutive week of therapy, the AUC averaged 110 +/- 16 micromol/L/min.",Phase I trial and pharmacokinetic study of all-trans-retinoic acid administered on an intermittent schedule in combination with interferon-alpha2a in pediatric patients with refractory cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9363862/),[μM] / [l·min],110,270800,DB00034,"Interferon Alfa-2a, Recombinant"
,10349689,time to maximum concentration,"Ribavirin is rapidly absorbed after oral administration (time to maximum concentration = 1.5 hours), followed by rapid distribution and prolonged elimination phases.",The clinical pharmacology of ribavirin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10349689/),h,1.5,272045,DB00034,"Interferon Alfa-2a, Recombinant"
,10349689,absolute bioavailability,"Ribavirin appears to be extensively absorbed; however, absolute bioavailability is approximately 50%, probably due to first-pass metabolism.",The clinical pharmacology of ribavirin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10349689/),%,50,272046,DB00034,"Interferon Alfa-2a, Recombinant"
,10349689,Apparent volume of distribution,"Apparent volume of distribution is extensive (approximately 2,000 L) due to ribavirin's distribution into nonplasma (cellular) compartments, which occurs via es-nucleoside transporters.",The clinical pharmacology of ribavirin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10349689/),l,"2,000",272047,DB00034,"Interferon Alfa-2a, Recombinant"
,10349689,half-life,"Because of slow elimination of ribavirin from nonplasma compartments, the multiple dose half-life is approximately 298 hours.",The clinical pharmacology of ribavirin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10349689/),h,298,272048,DB00034,"Interferon Alfa-2a, Recombinant"
